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Byunghee Koh 
 
TRANSCRIPTION FACTORS AND CIS-ACTING ELEMENTS IN T HELPER CELL 
CYTOKINE EXPRESSION 
 
The immune system provides resistance to the myriad of pathogens in the 
environment, but can also respond inappropriately causing allergic inflammation and 
autoimmune disease. CD4+ T cells, which play a crucial role in adaptive immune system, 
can be divided into several subsets based on their effector functions. T helper 9 (Th9) 
cells, derived by the IL-4/STAT6 and TGF-β signaling pathways, produce IL-9 as a 
hallmark cytokine, as well as IL-10. Through IL-9 production, Th9 cells protect against 
parasite infection but are also involved in allergic inflammation and autoimmune diseases. 
Transcription factors that promote Th9 development include STATs, PU.1, BATF, and 
IRF4. In this study, we identify ETV5 as a factor that promotes IL-9 and IL-10 production 
by binding to cis-acting regulatory elements in the respective genes. At the Il9 gene, ETV5 
cooperates with PU.1 in regulating gene expression. At the Il10 gene, ETV5 facilitates 
binding of other transcription factors to the locus. These studies and others suggested that 
there may be additional cis-acting regulatory elements in the Il9 gene. We demonstrate 
that a conserved noncoding sequence (CNS) located 25 kb upstream of the Il9 
transcription start site, termed Il9 CNS-25, is critical for regulating Il9 expression in Th cell 
subsets. Th9 cells derived from Il9 CNS-25 mutant (Il9 ΔCNS-25) mice produce significantly 
less IL-9. Il9 CNS-25 promoted chromatin modifications at the promoter and accessibility 
of the locus. Il9 ΔCNS-25 mice showed attenuated airway inflammation compared to control 
mice. The Il9 CNS-25 region in mice is conserved with an IL9 CNS-18 region in the human 
genome. We deleted CNS-18 in primary human Th9 cells and observed diminished IL-9 
production. Thus, we have identified transcription factors that regulate multiple cytokines 
vii 
in Th cell lineages and have demonstrated that the Il9 CNS-25/IL9 CNS-18 elements are 
respectively critical for Il9/IL9 gene expression. 
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1 
INTRODUCTION 
Innate and adaptive immunity 
The immune system provides resistance to the myriad of pathogens in the 
environment, but can also respond inappropriately causing allergic and autoimmune 
diseases (1). The immune system can be largely classified into innate immunity and 
adaptive immunity. Innate immunity is a fast and non-specific first line of defense. The 
adaptive immunity is pathogen-specific, and provides long-lasting protection, contributing 
fast and effective protection against repeat infections. Therefore, innate and adaptive 
immunity cooperate to enhance protection against harmful foreign agents (1).  
 
Innate immunity 
Humans and other mammals are constantly exposed to various toxic substances 
such as pathogens or nontoxic allergens such as pollen. Physiologic barriers, part of 
innate immunity, provide a crucial first defense line against pathogens. The first barriers 
to the environment are the epithelial cell layers that are tightly connected between cells 
through cell-cell connections in the skin and mucosal layers. Epithelial cells also produce 
protective enzymes and antibacterial peptides in tears and saliva, and provide a low pH 
environment in stomach. Mucosal cells also contribute to the initial defense in the 
respiratory and gastrointestinal tracts by secreting mucus. Additionally, commensal 
microorganisms that reside at epithelial surfaces compete with harmful bacteria for space 
and nutrients to survive. 
When pathogenic microorganisms cross the epithelial layer, various types of innate 
immune cells recognize and kill the pathogens by ingestion. The innate immune response 
is very fast upon pathogen exposure and innate immune cells immediately generate 
inflammatory mediators for protection. Innate immunity consists of cellular and humoral 
components. Innate immune cells are cellular components which include macrophages, 
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dendritic cells, mast cells, neutrophils, eosinophils, natural killer (NK) cells, and NK T cells. 
Humoral components including complement proteins, mannose binding lectin, 
lipopolysaccharide (LPS) binding protein and anti-microbial peptides, augment the activity 
of innate immune cells. Innate immune cells express invariant, germline encoded 
receptors that recognize pathogen associated molecular patterns (PAMPs) which are 
highly conserved microbial components or damage-associated molecular patterns 
(DAMPs), which are metabolic consequences of infection and inflammation. One of the 
families of pattern recognition receptors (PRRs) recognizing PAMPs are the Toll-like 
receptors (TLRs). There are 10 TLRs in humans and each TLR specifically recognizes 
microbial products. For example, TLR4 recognizes LPS, a component of the outer 
membrane of Gram-negative bacteria and TLR5 recognizes flagellin. TLR3 and TLR7 
recognize double-stranded RNA and single stranded RNA respectively. Leucine-rich 
repeat containing receptor (NLR), one of the cytosolic PRRs, can recognize endogenous 
signals of cellular damage such as K+ efflux and uric acid crystals. Neutrophils recognize 
and engulf microorganisms and digest them through intracellular vacuoles containing toxic 
effector molecules such as nitric oxide, superoxide and degradative enzymes. Neutrophils 
accumulate at the site of bacterial infections and produce large quantities of toxic reactive 
oxygen species, enzymes, cytokines such as TNF and IL-12, as well as chemokines. 
Macrophages and monocytes are recruited to the infection site and persist for long period. 
Macrophages also act as antigen presenting cells (APC). Eosinophils have prominent 
cytoplasmic granules containing toxic molecules which effectively eliminate helminthic 
parasites. Mast cells are a key player in the initiation of immediate hypersensitivity 
responses. Mast cells express FcεRI, high-affinity IgE receptor. After binding of antigen 
specific IgE, mast cells are sensitized. Upon exposure to the same antigen, mast cells 
rapidly release histamine and other inflammatory cytokines that stimulate tissue 
inflammation. NK cells, large granular lymphocytes, recognize virus-infected cells or tumor 
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cells and kill them by releasing cytotoxic granules that induce apoptosis of target cells. 
Through inhibitory receptors on their surface, NK cytotoxic activity is inhibited when their 
receptors bind to the self-major histocompatibility complex (MHC) molecules. Dendritic 
cells (DCs) are present in most tissues and express both MHC II and I molecules that are 
recognized by CD4+ and CD8+ T cells respectively. After ingestion of foreign antigens, DCs 
migrate to the draining lymph nodes (dLNs) via afferent lymphatics through chemokine 
receptors such as CCR7 and CCR8. In the lymph nodes, DCs process antigens and load 
peptides on the MHCII molecules which are recognized by T cell receptor (TCR) on naïve 
CD4+ T cells (1, 2).   
 
Adaptive immunity 
During development in the thymus and the bone marrow, T and B lymphocytes 
express a randomly generated repertoire of T and B cell receptors through somatic gene 
recombination. Naïve T lymphocytes develop in the thymus, a primary lymph node, and 
circulate in the blood and enter the dLNs, secondary lymph nodes. In the dLNs, T cells 
are activated through interactions between TCR and MHC molecules. MHC I is 
constitutively expressed by all nucleated cells, while MHC II is expressed on APCs (1, 3).   
CD8+ T cells, also called cytotoxic T cells (CTL) when they are primed, express 
the CD8 coreceptor for MHC I. By recognizing cytosolic antigenic peptides bound to MHC 
I, CD8+ T cells kill target cells infected with intracellular pathogens or tumor cells through 
cell-cell contact. Using CTL granules containing granzymes and perforin, CD8+ T cells 
induce lysis or apoptosis of target cells. Additionally, TCR activation promotes Fas ligand 
(CD95L) expression on the CD8+ T cells which bind to Fas (CD95) on the target cells 
leading to apoptosis of the target cells. Most CD4+ and CD8+ T cells have a TCR consisting 
of α and β chains. Unlike these αβ T cells, γδ T cells have a TCR consisting of γ and δ 
chains that  recognize mycobacterial antigens presented by the CD1 family and through 
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other less well-defined mechanisms. Natural killer T cells (NKT), another subset of T cells, 
are characterized by the expression of the NK receptor and invariant TCR. NKT cells 
recognize glycolipid antigens presented by CD1d on APCs. Upon TCR activation, NKT 
cells rapidly release large amounts of cytokines such as IL-4, IFN-γ and IL-9, contributing 
to the regulation of immune responses. Adaptive humoral immunity is mediated by 
antibodies produced by plasma cells that develop from B cells. B cells produce five classes 
of immunoglobulins (Igs): IgA, IgD, IgE, IgG and IgM, which are classified based on their 
amino acid sequence in the constant region of antibody heavy chain.  B cells develop in 
the bone marrow and express the B cell receptor (BCR) consisting of membrane bound 
Igs. In germinal centers (GCs), located inside of lymph nodes, B cells encounter follicular 
helper T (Tfh) cells. Tfh cells promote the development of memory B cells and long-lived 
plasma cells. IL-4, secreted by Tfh, mediate class switch of antibodies in B cells (1, 3). 
 
CD4+ T helper cells 
CD4+ T cells play an essential role in adaptive immune system. With the help of 
APCs, naïve CD4+ T cells differentiate into Th subsets to regulate host defense and 
inflammatory responses (Figure 1). For optimal Th cell activation, APCs need to provide 
three signals to induce lineage specific transcription factors (LSFs) that promote the 
differentiation of naïve CD4+ T cells. TCR signal is the first signal through the interaction 
between the TCR on the naïve CD4+ T cells and the antigen peptide-MHC II complex on 
the APCs. Co-stimulatory signals are the second signals mediated by cell surface 
molecular interactions in a non-antigen dependent mechanism. For example, the co-
stimulatory molecule CD28 on naïve CD4+ T cells interacts with its corresponding ligands 
CD80 or CD86 on the APCs. The third signal is mediated by cytokines, which can activate 
the signal transducer and activator of transcription (STAT), Smads and NF-κB signaling 
pathways thereby inducing a number of pertinent TFs (4).  
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Each CD4+ T helper cell subsets has its own specific master regulators that 
promote effector functions by inducing a subset specific cytokines. Th1 cells express T-
bet and produce IFN-γ which stimulates macrophages to eliminate intracellular bacterial 
pathogens (5, 6). IL-12 binds to the IL-12 receptor which consists of IL-12Rβ1 and IL-
12Rβ2, and activates STAT4 which collaborates with T-bet to promote IFN-γ production. 
IFN-γ further amplifies IFN-γ production by binding to the IFN-γ receptor which stimulates 
STAT1 signaling to promote T-bet expression (6-8).  
Th2 cells express GATA3 and produce IL-4, IL-5 and IL-13 which further activate 
innate immune cells such as eosinophils. STAT6 activated through the IL-4 receptor, 
promotes the expression of GATA3 and Th2 cell specific cytokines (9-11).  
Th17 cells express the master regulator RORγt and produce IL-17. Along with 
TGF-β signaling, a STAT3 signaling pathway activated by IL-6, IL-21 and/or IL-23 
promotes Th17 cell development (12, 13). IL-17 is an important cytokine for protection 
against fungi and extracellular bacteria and is also known as a pro-inflammatory cytokine 
(14, 15). Th17 cells are involved in many autoimmune and allergic disease such as 
rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) (16).  
Tfh cells express B-cell lymphoma 6 (Bcl6) which promotes Tfh cell differentiation 
while preventing differentiation of Th1, Th2 and Th17 cells. Tfh cells play an essential role 
in germinal center reactions which are important for antibody production. Tfh cells produce 
IL-4 which allows B cells to switch antibody class from IgM to IgE. The IL-6/STAT3 axis 
and the inducible costimulator (ICOS) signaling pathway induce Bcl6, basic leucine zipper 
transcription factor (BATF) and Interferon regulatory factor 4 (IRF4) which are important 
for Tfh cell development (17-19).  
Foxp3+ regulatory T (Treg) cells play a pivotal role in maintaining immune tolerance 
and controlling immune responses. Treg cells are also known as suppressor T cells 
because they repress Th cell effector functions (20, 21). Foxp3 promotes and maintains 
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Treg cell population by interacting directly or indirectly with numerous TFs. Foxp3 belongs 
to the forkhead-box/winged-helix transcription factor family, and the Foxp3 gene is located 
on the X chromosome (21, 22). Foxp3 mutations cause severe autoimmune and 
inflammatory diseases which are associated with a significant increase in Th1 cytokines. 
These diseases are called IPEX (immune dysregulation, poly-endocrinopathy, 
enteropathy, X-linked syndrome) in humans (23). Foxp3 mutant mice called “Scurfy”, show 
similar symptoms of IPEX, and these symptoms are relieved by introducing wild type (WT) 
Treg cells (21, 24). Treg cells use different suppressive mechanisms in lymphoid and non-
lymphoid tissues. In lymphoid tissues, Treg cells suppress effector T cells by preventing 
dendritic cell maturation or directly inhibiting activation of effector T cells. In non-lymphoid 
tissues, Treg cells secrete inhibitory cytokines such as IL-10, IL-35 and TGF-β (25).   
 
 
Figure 1. Model of differentiation and functions of Th cell subsets 
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Cytokines 
Cytokines are soluble proteins secreted by various types of cells including immune 
cells. Cytokines have distinct roles in the immunoregulation and inflammation. Cytokines 
regulate the differentiation and proliferation of T cells through the Jak/STAT pathways. 
Cytokines induce lineage specific TFs that are important for the development of Th cell 
subsets. After differentiation, Th cells sense their cognate antigens and environmental 
cytokines to control immune responses by secreting Th cell specific effector cytokines. 
For optimal functions, the expression of cytokines needs to be strictly regulated (4). 
 
Interleukin-10 
IL-10, encoded by the Il10 gene, is a critical regulatory cytokine produced by many 
Th subsets including Th2 and Th9 cells. As an anti-inflammatory cytokine, IL-10 
suppresses inflammatory responses at the mucosal surfaces (26). In the absence of IL-
10, mice develop spontaneous autoimmune inflammation (27). However, increased IL-10 
production prevents clearance of pathogens resulting in chronic infection. Thus, 
transcriptional control of the Il10 gene is essential in maintaining disease-free immune 
homeostasis (28). 
 
Interleukin-9  
IL-9, encoded by the Il9 gene, is a 40kDa glycoprotein with 144 amino acids. 
Interleukin-9 was firstly discovered by stimulating murine T helper cell lines with 
concanavalin A (29). Naïve murine T cells cultured with IL-2, IL-4 and TGF-β express IL-
9 (30). Secreted IL-9 binds to the IL-9 receptor (IL-9R), also known as CD129, which is a 
heterodimeric protein consisting of the IL-9Rα chain and the common γc chain (31, 32). 
IL-9R is expressed on various immune cells and mucosal layer cells such as smooth 
muscle cells in the lung or epithelial cells in the gut and lung (32-36). Upon binding of IL-
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9 to its receptor, JAK1 and JAK3 are activated by phosphorylation leading to the activation 
of STAT1, STAT3 and STAT5 (37). As other cytokines, IL-9 functions pleiotropically, as a 
positive or negative regulator of immune responses. IL-9 contributes to allergic 
inflammation and autoimmune diseases. IL-9 is critical for protection against parasites 
such as helminths, for tumor immunity and for immunological tolerance during allograft 
skin transplantation (38). In the following section, the roles of IL-9 in immunity and 
diseases will be discussed in more details  
 
Allergic asthma and atopic diseases 
Allergic asthma is a chronic inflammatory disease of the lung airways 
characterized by coughing, wheezing and shortness of breath which is caused by airflow 
obstruction. In response to the allergens, the innate and adaptive immune systems are 
highly activated and mediate mucosal inflammation by recruiting eosinophils to the 
airways or by secreting proinflammatory mediators such as histamine (39). 
Constitutive expression of IL-9 in the lung of transgenic mice causes airway 
inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness (40). Genetic 
studies in asthmatic patients showed that genes related to asthma or atopy are located 
near on chromosome 5q31-q33, and the Il9 gene is also located near on this chromosome 
(41). Asthmatic patients show higher serum IgE levels, Il9 gene expression and a higher 
number of IL-9 producing cells (Th9) in the airways compared to healthy subjects (42-45). 
IL-9 receptor expression in airway epithelial cells, correlates with a high level of mucus 
production, and is also higher in asthma patients (46). IL-9 activates lung smooth muscle 
cells to produce cytokines and chemokines such as eotaxin which recruits eosinophils to 
the airways (47). IL-9 also stimulates airway epithelial cells resulting in goblet cell 
hyperplasia and a high amount of mucus production that leads to bronchial 
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hyperresponsiveness (48-50). IL-9 also acts as a growth factor for mast cells (51) and 
enhances IL-4 mediated IgE and IgG production by B cells (52, 53). 
As a main source of IL-9, the Th9 cells are critical for the development of allergic 
airway disease. Increased numbers of Th9 cells are detected in asthmatic and atopy 
patients, and these patients express high levels of genes related to Th9 cell development 
and function (42-45). In experimental models of asthma, Th9 cells mediate allergic 
inflammation through their production of IL-9 (42, 54-56). Adoptive transfer of in vitro 
cultured Th9 cells into Rag2-deficient mice promotes allergic inflammation characterized 
by mast cell accumulation and mucus production, and these symptoms are ameliorated 
through administration of an IL-9 neutralizing antibody (55). IL-9, produced by Th9 cells, 
is required for accumulation of mast cells in the airways during asthma (57). These 
features of inflammation are attenuated by natural or engineered deficiencies in the IL-9-
inducing TFs such as BATF, IRF4 and PU.1 (42, 44, 54-59).  
 
Inflammatory bowel disease (IBD) 
Inflammatory bowel diseases such as Crohn’s disease (CD) and ulcerative colitis 
(UC) are characterized by chronic inflammation of the gastrointestinal tract that leads to 
chronic diarrhea and abdominal pain (60-62). IBD is caused by deregulated activation of 
several Th cell subsets. Th1 cells, activated by IL-18, IL-12 and IL-23, secrete IFN-γ which 
is essential for CD pathogenesis. Th2 cells produce Th2 specific cytokines inducing UC. 
Th17 cells, activated by IL-23 and IL-6, produce IL-17A/F, IL-21 and IL-22 contributing to 
both CD and UC (63-65). IBD patients show higher number of IL-9 producing cells and 
higher gene expression of Il9 and Il9r compared with healthy people (66). In an oxazolone 
induced colitis model, Th9 cells promote UC by regulating intestinal epithelial cells. In that 
study, mice with PU.1 deficient T cells are resistant to colitis and IL-9 neutralizing antibody 
treatment attenuates inflammation (66). Moreover, IL-9 producing invariant NKT cells are 
10 
important for protection against autoimmune inflammation in the dextran sulfate sodium 
(DSS)-induced colitis model (67).  
 
Multiple sclerosis  
In addition to induction of allergic inflammation in the lung and gut, Th9 cells are 
also involved in multiple sclerosis, a T cell dependent demyelinating disease (68, 69). Th1 
and Th17 cells are known as key players in an experimental animal model of multiple 
sclerosis (70). During an experimental autoimmune encephalomyelitis (EAE), both Th17 
and Th9 cells produce IL-9, and IL-9 neutralization or IL-9Rα deficiency attenuate disease 
progression. Transfer of myelin oligodendrocyte glycoprotein (MOG) specific Th9 cells into 
RAG deficient recipient mice promotes EAE (69, 71, 72). However, other studies showed 
IL-9Rα deficient mice develop more severe EAE due to the fact that IL-9 can also have 
anti-inflammatory function in EAE by enhancing Treg cell activity (33, 73).  
 
Rheumatoid arthritis (RA)  
RA is a chronic autoimmune disease mediated by autoreactive Th1, Th17 cells 
and impaired function of Treg cells (74). In an experimental antigen induced arthritis model, 
IL-9 produced by type 2 innate lymphoid cells (ILC2) acts as an autocrine growth factor 
and upregulates ICOS ligand and glucocorticoid-induced TNFR-related protein (GITR) 
ligand on ILC2. Through interaction with these ligands, Treg cells enhance suppressive 
activity which inhibits Th17 cell mediated inflammation. Therefore IL-9 is critical for 
resolution of joint inflammation in RA (75).  
 
Parasite infections 
During nematode infections such as a Nippostrongylus brasiliensis infection, Th9 
cells are essential for expulsion of the parasites from gastrointestinal tract (76). IL-9, 
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produced by Th9 cells, stimulates mast cells to secrete inflammatory mediators that 
stimulate epithelial cells to produce mucus, recruits eosinophils, increases intestinal 
permeability, and induces smooth muscle contraction (76).   
 
Tumor immunity 
Depending on the types of cancer, Th9 cells can function positively or negatively 
in tumor growth (77-81). In a melanoma model, adoptive transfer of Th9 cells into RAG 
deficient recipient mice following B16-F10 melanoma cancer cell injection reduces tumor 
growth compared to control (77, 78). Additionally, Il9 deficient mice and mice treated with 
IL-9 neutralizing antibody show accelerated tumor masses. In this model, the roles of IL-
9 in antitumor immunity depend on mast cell activation (77). Tumor specific Th9 cells 
promote CD8+ CTL mediated anti-tumor immunity (78). IL-21 produced by Th9 cells also 
has an anti-cancer function by promoting CD8+ CTL responses and IFN-γ production (81).  
 
Cellular sources of IL-9 
IL-9 can be produced by a number of immune cell populations. In this segment, 
we briefly discuss evidence for IL-9 production and function in these cells. 
 
Type 2 innate lymphoid cells (ILC2)  
Innate lymphoid cells (ILC), newly discovered immune cells, are groups of lineage 
negative lymphoid cells (82). These cells lack T, B cell receptors and other lineage 
markers, however their functions are similar to T helper cells. There are three types of 
ILCs: ILC1, ILC2 and ILC3. ILC2 secrete Th2 type cytokines such as IL-5, IL-6, IL-13 and 
IL-9 in response to helminth infection (76, 83). Moreover, ILC2 are the main source of IL-
9 during papain induced lung inflammation (83). 
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Mast cells 
Mast cells secrete both cytokines and pro-inflammatory mediators such as IL-6 
and histamine. Toll-like receptor agonists and cytokines including IL-10 and IL-9 stimulate 
mast cells to produce IL-9 (84-86). As a growth factor, IL-9 is also important for survival 
and proliferation of mast cells (51). A recent study revealed that IL-9 producing mucosal 
mast cells (MMC9s) induce anaphylaxis in response to food antigens by producing IL-9 
and inflammatory mediators (87).  
 
Natural killer T (NKT) cells  
NKT cells produce Th2 type cytokines and IL-9 in vitro (67). In allergic inflammation 
models, CD1d restricted NKT cell deficient mice are resistant to allergic inflammation 
caused by decreased IL-9 production from NKT cells and by reduced mast cell recruitment 
(88). Another study revealed that IL-9 producing NKT cells protect against DSS induced 
colitis. In this study, NKT cells cultured under Th9 condition produced IL-9. Additionally, 
α-galactosylceramide (α-GalCer) treated NKT cells produced more IL-9 compare to non-
treated controls (67).  
 
Th9 cells – IL-9 producing T cells 
Th9 cells are the most recently described Th cell subset and are derived by the IL-
4/STAT6 and TGF-β signaling pathways (32, 68, 89). Th9 cells are characterized by a 
high amount of IL-9 production and a high expression of PU.1, a master regulator for Th9 
cell development (59). Th9 cells also express a high amount of IL-10, however Th9 cells 
do not co-express IL-4, IL-5, IL-13, IL-17 or IFN-γ. Like other Th cell subsets, Th9 cells 
can function as both positive and negative regulator of immune responses. Th9 cells 
protect against extracellular parasites such as helminths and important for anti-tumor 
immunity (76-78). However, Th9 cells are also involved in allergic inflammation or 
13 
autoimmune disease (42, 54-56). Therefore, Th9 cell development and IL-9 production 
need to be strictly regulated. To do this, many TFs cooperate with cis-regulatory elements 
near the Il9 gene.   
 
Regulation of Th9 cell development 
Cytokines activate STAT signaling pathways which induce TFs involved in Il9 
expression (Figure 2). These TFs promote Il9 expression by directly binding to the Il9 
promoter or by mediating the Il9 locus chromatin remodeling to a poised status ready to 
be activated in response to TCR stimulation. TCR signaling activates NFAT and NF-κB, 
enhancing Il9 expression by binding to the Il9 promoter (38).  
 
STAT6 
IL-4 binds to the IL-4 receptor (IL-4R), consisting of the IL-4Rα and γc chains, and 
activates STAT6 through JAK activation (10). STAT6 regulates Il9 expression in several 
ways (Figure 2). STAT6 directly binds to the Il9 promoter and promotes IL-9 production 
(90). Previous report showed that STAT6 represses Foxp3 and Tbx21 which repress IL-9 
production (90). Moreover, STAT6 induces IL-9 inducing TFs such as BATF and IRF4 (54). 
BATF is required for Th9 cell development as well as Th17, Tfh and Th2 cells. BATF 
deficiency impairs Th9 cell development and BATF deficient mice show attenuated airway 
inflammation in asthma model. Moreover, ectopic expression of BATF increases IL-9 
production in Th9 cells. Like STAT6, BATF also directly binds to the Il9 promoter and 
enhances Il9 expression (54). IRF4 is another essential TF for Th9 cell development as in 
Th17 and Th2 cell development. IRF4 deficiency resulted in significantly less IL-9 
production under Th9 cell condition and ectopic expression of IRF4 increases IL-9 
production in Th9 cells. Moreover, mice with IRF4 deficient T cells show attenuated airway 
inflammation in the acute OVA/Alum asthma model (55).  
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BATF and IRF4 cooperate to regulate Th17 cell development (91, 92). BATF and 
IRF4 cooperatively bind to specific DNA elements called “activating protein 1-IRF 
composite elements (AICEs)” to enhance Th17 cell differentiation and gene expression 
(93, 94). In Th9 cells, BATF and IRF4 also cooperatively bind to the Il9 promoter. 
Deficiency of either TF impairs the binding of the other TF to the Il9 promoter, and mutation 
of AICE in the Il9 promoter decrease Il9 promoter reporter activity (54).   
GATA3, a master regulator of Th2 cells, is also induced by IL-4/STAT6 signaling 
pathway in Th9 cells although expression is lower than in Th2 cells (32, 90). The function 
of GATA3 in Th9 cell development is controversial because GATA3 deficient T cells fail to 
produce IL-9 (68), whereas ectopic expression of GATA3 inhibits IL-9 production in Th9 
cells (90). These data suggest that balancing GATA3 expression is important for optimal 
Il9 expression. 
 
STAT5 
IL-2 binds to the IL-2 receptor, a heterotrimeric complex consisting of IL-2Rα called 
CD25, IL-2Rβ and γ chains, and activates STAT5 (89). The IL-2/STAT5 signaling pathway 
is also critical for Th9 cell development. Either IL-2 or STAT5 deficient T cells fail to 
produce IL-9 under Th9 cell condition (89, 95). STAT5 positively regulates Il9 expression 
directly and indirectly. STAT5 directly binds to the Il9 promoter and enhances Il9 
expression. STAT5 competes with Bcl6, a master regulator of Tfh cells and a repressor of 
Il9 expression by binding to the Il9 promoter, to bind to the Il9 promoter and repress Bcl6 
expression (71, 95)  
Thymic stromal lymphopoietin (TSLP), an epithelial cell derived cytokine, is critical 
for Th2 mediated allergic inflammation (96). TSLP also induces Il9 expression by 
activating STAT5 that binds to the Il9 promoter. IL-2 neutralization does not affect the 
15 
ability of TSLP to induce Il9 expression, suggesting that TSLP function is independent of 
IL-2 (42).  
 
STAT3 
STAT3 might function differently in mouse and human Th9 cells. Mouse Th9 cells 
produce a high amount of IL-10 which acts as a negative regulator of Il9 expression (97). 
STAT3 deficient Th9 cells produce a relatively high amount of IL-9 at later differentiation 
stages meaning that activation of STAT3 by IL-10 results in instability of the Th9 cell 
phenotype. Additionally, IL-10R blockade using anti-IL-10R antibody contributes to the 
maintenance of IL-9 production (97). In contrast to murine Th9 cells, human Th9 cells 
produce more IL-9 in response to IL-10. In addition to IL-10, IL-6 and IL-21 also promote 
IL-9 production by activating STAT3 in human Th9 cells (98).  
 
TGF-β signaling pathway 
TGF-β can reprogram Th2 cells into Th9 cells (32, 68). TGF-β binds to the TGF-
βR2 and activates Smad2, 3 and 4. The TGF-β signaling pathway induces active histone 
modifications at the Il9 promoter (58, 99). By physical interaction with IRF4, Smad2/3 
promote Il9 expression by directly binding to the Il9 promoter (58). Smad3 is also required 
for Notch signaling mediated Il9 expression (73).  
TGF-β signaling pathway also induces the expression of PU.1. PU.1 is a member 
of E-Twenty-Six (ETS) TF family and induced by a Smad independent TGF-β signaling 
pathway (59, 90, 100). PU.1 is the only TF that can induce Il9 expression in cells other 
than Th9 cells. Ectopic expression of PU.1 in Th2 cells increases IL-9 production and 
decreases IL-4 expression. PU.1 deficient Th9 cells produce significantly less IL-9 and 
more IL-4, suggesting that PU.1 negatively regulates Th2 cell development (59). PU.1 
directly binds to the Il9 promoter and promotes Il9 expression through permissive histone 
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acetylation at the Il9 locus by recruiting GCN5, a histone acetyltransferase (HAT) (101). 
Mice with PU.1 deficient T cells are resistant to in vivo airway inflammation model (59).  
 
Etv5 
Etv5, or Ets variant gene 5, is an ETS family member that has largely been 
examined for its roles in tissue development. Etv5 coordinates limb development, controls 
spermatogonial gene expression, and regulates epithelial-mesenchymal gene expression 
(102-105). Etv5 was also identified as an IL-12-induced Th1 gene, though recent work 
suggests it only has a minimal role in IFN-γ production, contrary to the original report (106, 
107). Etv5-deficient T cells have diminished Th17 but slightly increased Th2 development 
in vivo, and this correlates with decreased inflammation in the house dust mite model of 
allergic lung inflammation. The diminished pulmonary inflammation is due to the lack of 
IL-17-dependent immunity, because the addition of exogenous pulmonary IL-17 to Etv5 
conditional mutant mice normalizes inflammation (107).  
 
Foxo1 
Forkhead box protein O1 (Foxo1) is required for IL-9 production in Th9, Th2, Th17 
and Treg cells (108). The PI3K/AKT pathway negatively regulates Foxo1 activity. In the 
nucleus, Foxo1 is phosphorylated by AKT and moves out of the nucleus to the cytosol 
leading to inactivation of its transcriptional activity. Foxo1 directly binds to the Il9 and Irf4 
promoters and promotes gene expression. Loss of Foxo1 through siRNA leads to less IL-
9 production in Th9 and Th17 cells resulting in attenuated allergic inflammation (108).  
 
Co-stimulation 
Like other Th cell differentiation pathways, CD28 stimulation by CD80/CD86 on 
APCs is critical for Th9 cell development. The CD28/CD80 or CD86 stimulation transiently 
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activate NF-κB and NFAT which directly bind to the Il9 promoter (109, 110). The ligation 
of OX40 on T cells by the OX40 ligand on APCs induces IL-9 in Th9 cells. OX40 activates 
the TRAF6, an ubiquitin ligase, which activates NF-κB-inducing kinase (NIK) and the 
noncanonical NF-κB signaling pathway to induce IL-9 (109). Notch and Smad3 cooperate 
to induce IL-9. The ligation of Notch on T cells by the Jagged2 on APCs promotes Th9 
cell development. After ligation, the Notch1 intracellular domain (NICD1) moves to the 
nucleus and interacts with Smad3 to bind to the Il9 promoter (73).  
 
 
Figure 2. Transcriptional network for Il9 expression in Th9 cells 
 
 
 
Regulation of gene expression 
For specific and precise gene regulation in different cell types, cooperation of TFs, 
trans- regulatory elements, and cis-regulatory elements is critical. TFs recognize and bind 
to specific DNA sequences in the genome through DNA binding domains, and these TFs 
recruit other TFs such as histone modifying enzymes through activation or other 
interaction domains (111).   
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Epigenetic pioneering TFs act to initiate gene expression by converting closed 
chromatin to open chromatin. DNase I hypersensitive sites (DHS) are the result of less 
tightly packaged nucleosomes or the absence of nucleosomes. The nucleosome is a basic 
structural unit of DNA packaging, and consists of 146 base pairs (bp) of DNA wrapped in 
histone octamer - two copies of core histones: H2A, H2B, H3 and H4. TFs can’t bind to 
highly nucleosome packed regions, called heterochromatin. However, nucleosome free 
regulatory elements, called euchromatin, are accessible to lineage specific TFs which 
dictate lineage specific chromatin landscape by recruiting chromatin remodeling 
complexes such as HATs and histone methyltransferases (HMTs). These epigenetic 
modifications on cis-regulatory elements allow the binding of other TFs to regulate gene 
expression (112-115). 
Recent various genome wide association studies (GWAS) have revealed that 
almost 90% of disease related single nucleotide polymorphisms (SNPs) are enriched in 
the intronic and intergenic regions. Many SNPs in cis-regulatory elements are closely link 
to diseases and these mutations affect the binding of TFs and chromatin conformation 
which result in abnormal gene expression (112, 116-118). 
 
Cis-regulatory elements 
There are several types of cis-regulatory elements: promoters, enhancers, 
silencers, insulators and locus control regions (LCRs). These cis-elements are located in 
different regions of the gene (119) These regions can be evolutionarily highly conserved 
between species and provide binding sites for multiple TFs to control gene expression 
(120). Accessibility of TFs to these regions is regulated by epigenetic mechanisms such 
as DNA methylation, histone modifications, chromatin remodeling and intra/ inter-
chromosome interactions (111).  
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Enhancers 
The location of enhancers varies among genes. Distal enhancers can be located 
far from a gene transcription start site (TSS), and a DNA loop mediates enhancer-
promoter interactions (Figure 3)(121, 122). Active enhancers are characterized by high 
DNase1 sensitivity, strong binding of p300, co-ocupation of TFs, and active histone 
modification marks such as H3K4me1, H3K4me2 and H3K27ac, but low H3K4me3, an 
active promoter marker (123). 
Histone modifications are one of the key post transcriptional gene regulation 
mechanisms. Histone tails can be modified with methylation, acetylation, phosphorylation, 
ubiquitylation and sumoylation (111). Chromatin status is defined as “poised”, “active” or 
“silent” depending on modifications of histone tails which affect gene expression patterns 
(124-127).  
Mono or di-methylation of lysine (K) 4 residue in Histone 3 (H3) tail is a poised or 
primed enhancer marker which is strictly regulated by HMTs. H3K4me1 modified 
enhancers without H3K27ac are termed as “poised” -ready to be activated by subsequent 
stimulation. Enhancers marked by both H3K4me1 and H3K27ac are termed as “active”-
opened chromatin status which allows the binding of TFs (128). Acetylation of tails of H3 
such as H3K27ac is a critical mechanism for active gene expression and it is strictly 
regulated by histone deacetylases (HDACs) or HAT such as p300 (129, 130). Active 
promoters are marked by H3K4me3 and active transcription elongation is marked by 
H3K36me3 which is spread throughout the gene body (131). H3K27me3, catalyzed by 
histone methyltransferase Ezh1 or Ezh2, a subunit of polycomb repressive complex2 
(PRC2), is associated with “silent” enhancer- repressive and closed chromatin status. The 
H3K4me3 and H3K27me3 bi-functional pattern is distinct among Th cell subsets (132).  
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TFs shaping the epigenetic landscape in differentiating Th cells 
In naïve CD4+ T cells, most gene loci of lineage specific TFs and cytokines are 
inactive or have a repressed status marked by low DNase1 sensitivity and repressive 
histone modifications. After TCR and cytokine stimulation, these gene loci are converted 
to permissive chromatin with high DNase1 sensitivity and active histone modifications 
which allow the binding of TFs. TCR signaling induces epigenetic pioneering TFs such as 
NFAT and AP-1 that regulate chromatin landscape and other general TFs. In combination 
with TCR stimulation, the STAT signaling pathway is essential for establishing lineage 
specific epigenetic landscapes required for Th cell development. STATs sense 
environmental cytokines secreted by APCs. After binding of a cytokine to a cytokine 
receptor, JAKs activate STATs, and dimerized STATs translocate to the nucleus and 
initiate Th cell specific gene expression (111).   
Recent genome wide studies showed that about 20% of the binding sites for 
STATs are located in promoters with the remainder located in regulatory regions or within 
genes. These data suggest that STATs are multifunctional, not only directly regulating 
gene expression but also initiating the chromatin landscape by inducing histone 
modification at regulatory elements through recruitment of p300 (8, 116, 133, 134). For 
example, STAT6 and STAT4 bind to enhancers and initiate lineage specific chromatin 
landscape through epigenetic modifications in Th2 and Th1 cell respectively (8).  
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Figure 3. Cooperation of TFs and enhancer for gene expression. STATs bind to the enhancer and mediate active histone modifications by recruiting p300, contributing to induce LSFs through DNA looping. Expressed LSFs bind to the enhancer with STATs and p300, leading to DNA looping which promote recruitment of RNA polymerase II (RNAPII) to the gene promoter.  
 
 
 
Enhancers for cytokine expression in Th cell subsets 
In Th cell subsets, cytokine loci are regulated by sophisticated enhancer structures 
which contribute to tightly regulated gene expression in response to various stimulations. 
In this section, the roles of enhancers in cytokine expression will be discussed in more 
details. 
 
Il10 regulatory elements  
The Il10 and IL10 genes are located on chromosome 1 in both mouse and human 
genomes. Both the Il10/IL10 genes include 5 exons (Figure 4) (135). The Il10 locus 
contains a promoter, intronic regions and several CNSs. CNS1 is located 5 kb upstream 
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of Il0 TSS. CNS2, CNS3 (+6.4) and CNS4 are located behind of 3’ of Il10 gene (136). 
However, not only these CNSs, conserved regions within Il10 gene provide binding sites 
for TFs. GATA3 regulates Il10 expression independently of IL-4 by binding to the Il10 
promoter, Il10 intronic region +3.7 and CNS3. By doing so, GATA3 induces permissive 
chromatin structure at the Il10 locus (137). E4 promoter-binding protein 4 (E4BP4) is a 
key player for Il10 expression in most Th subsets, and its function is independent on 
GATA3. In Th2 cells, E4BP4 binds to most intronic regions, CNS2 and CNS3, but not Il10 
promoter. E4BP4 deficient Th2 cells show repressive chromatin structure at the Il10 locus 
suggesting that E4BP4 epigenetically regulates the Il10 locus in Th2 cells (138). CNS3 
region contains AP-1 binding sites which allow the binding of c-Jun and JunB. In Th2 cells, 
these proteins bind to the CNS3 and promote Il10 expression. But these proteins do not 
activate Il10 promoter activity in reporter assays, suggesting that they might not bind to 
the Il10 promoter (136). In Th2 cells, IRF4 binds to both Il10 promoter and CNS3 
contributing to Il10 expression. In the absence of PU.1, IRF4 binds more strongly to the 
Il10 locus and enhances Il10 expression, suggesting that PU.1 acts as an Il10 repressor 
by inhibiting IRF4 activity (139). In Th1 cells, Ets-1, another ETS family member, 
negatively regulates Il10 expression by recruiting HDAC1 to the Il10 promoter and intronic 
regions (140). Therefore, Il10 regulatory elements and Il10-inducing or -repressing TFs 
cooperate to control Il10 expression.  
 
 
Figure 4. Schematic of the Il10 locus in mice 
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Il4-Il5-Il13 regulatory elements  
Th2 cells expressing cytokines such as IL-4, IL-5 and IL-13 are activated by the 
IL-4/STAT6 signaling pathway (141). IL-4 activates STAT6 which induce GATA3, an 
essential TF for Th2 cell development (9). STAT6 cooperates with GATA3 to mediate 
chromatin remodeling of Th2 cytokine locus (142). 
The Th2 cytokine locus, encoding IL-4, IL-5 and IL-13, contains more than 15 
DHSs. The Il13 locus located 12.5 kb behind of 3’ of the Il4 locus and the Il5 locus is 
located 86 kb upstream of the Il13 promoter. The Il4, Il13 and Il5 genes are coordinately 
regulated by Th2 LCR. Th2 LCR located between Il5 and Il13 promoters and contains 
Rad50 hypersensitivity site (RHS) 4-6. RHS6 and RHS7 sites provide binding sites for 
STAT6 and GATA3. GATA3 binds to these sites and recruits p300 to make these regions 
transcriptionally permissive. During differentiation, the Th2 LCR region is positioned 
adjacent to the Il4, Il5 and Il13 promoters by looping to promote gene expression (143). 
HS2, located in second intron of Il4 gene, is critical for IL-4 expression but dispensable for 
IL-5 and IL-13 expression (144).  Deletion of HS V, another DHS located downstream of 
Il4 gene, does not affect Th2 cytokines under Th2 cell condition, however deletion of this 
region impairs IL-4 and IL-13 expression in Tfh cells (145). GATA3 represses Tbx21 
expression by recruiting HDAC to the Tbx21 enhancer region during Th2 cell development 
suggesting that GATA3 acts as both positive and negative regulator in same Th cell 
lineage (146). 
 
Ifng regulatory elements  
Th1 cells producing IFN-γ are activated by the IL-12/STAT4 and STAT1 signaling 
pathway. Transcriptional regulation of IFN-γ is controlled by the Th1 specific TFs: T-bet, 
STAT1, STAT4 and STAT5. These TFs combinatorially regulate Ifng gene expression by 
binding to 12 enhancers in the Ifng locus (123, 147). In contrast to the Th2 cytokine locus, 
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the Ifng locus is dispersed in naïve CD4+ T cell and begin to close to the Ifng promoter 
during Th1 cell development (6, 148, 149). T-bet is important for recruiting CTCF, CCCTC 
binding factor, to enhancer regions which result in loops between enhancers and the Ifng 
promoter (148).  
 
Il17 regulatory elements  
Th17 cells produce proinflammatory cytokines such as IL-17A and IL-17F, two 
highly homologous cytokines. Th17 cells are differentiated from naïve CD4+ T cell by the 
TGF-β and STAT3 signaling pathways, the latter activated by IL-6, IL-21 and IL-23 (15). 
STAT3 directly binds to the Il17 gene promoter and induces Rorc which encodes RORγt, 
a master regulator of Th17 cell development (150, 151). In addition to RORγt, another 
orphan nuclear receptor RORα is also important for IL-17A and IL-17F expression (152). 
STAT3 mediates permissive histone modifications at the Il17 gene locus that contains the 
Il17a, Il17f promoters and eight CNSs (153, 154). CNS2, located upstream of Il17a, 
interacts with the Il17a and Il17f promoters leading to gene expression. Il17a and Il17f 
promoters do not contain ROR response element (RORE), a binding sequence for ROR, 
however CNS2 does have ROREs (152). Therefore, RORα and RORγt bind to the CNS2 
and mediate chromatin remodeling resulting in Il17 gene expression.  
 
Il9 regulatory elements  
The Th9 cells are main producer of IL-9. The Il9 gene is located on chromosome 
13 in the mouse genome and the IL9 gene is located on chromosome 5 in the human 
genome. Both Il9/IL9 genes consist of 5 exons. The Il9 locus contains 3 CNSs which are 
highly conserved between mice and human. CNS0 (-6) is located 6.3 kb upstream of the 
Il9 TSS, CNS1 is the promoter region of Il9, and CNS2 (+5.5) is located 5 kb behind of the 
Il9 TSS (Figure 5) (155). Many IL-9-inducing factors such as IRF4, BATF, STAT6 and 
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PU.1 directly bind to the Il9 promoter and promote Il9 expression (54, 55, 59, 90). STAT6 
also binds to the CNS-6 region in Th9 cells but binding strength is lower than in the Il9 
promoter (90). However, detailed functions of CNSs at the Il9 locus and existence of other 
enhancers for Il9 expression are not fully understood. 
 
 
Figure 5. Schematic of the Il9 locus in mice 
 
 
 
Research goals 
Transcription factors and cis-regulatory elements cooperately regulate gene 
expression. Many studies revealed TFs and cis-regulatory elements which regulate 
cytokines expression such as Il4-Il5-Il13, Il17a-Il17f, Ifng and Il10 loci. However, 
identification and functions of trans- and cis-regulatory elements in Il9 and Il10 loci are still 
not completely defined. The goals of this research are to identify transcription factors 
binding to cis-regulatory elements of Il9 and Il10 loci and to define new enhancers that 
promote Il9 gene expression.  
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MATERIALS AND METHODS 
Mice 
C57BL/6 and BALB/C mice were purchased from Jackson Laboratory (Bar Harbor, 
ME, USA). Etv5fl/fl mice were provided by Dr. Xin Sun (105). Etv5fl/fl mice were crossed 
with CD4-Cre transgenic mice to generate CD4 conditional Etv5 deficient mice (Etv5fl/fl 
CD4-Cre+). Etv5fl/fl CD4-Cre- littermates were used as wild-type (WT) control mice (107). 
Stat6 deficient mice and Irf4fl/fl Lck Cre+ mice were described previously (156, 157). CNS-
25 deleted mice (Il9 ΔCNS-25) were generated by CRISPR/Cas9 mediated gene editing 
(Taconic) (Figure 6 and Table 1). Mice were maintained under specific pathogen-free 
conditions. All experiments were performed with the approval of the Indiana University 
Institutional Animal Care and Use Committee. 
 
 
 
 
 
 
Figure 6. Strategy for generating Il9 ΔCNS-25 mice 
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aggtaattccaagtgtaacattgcacagtgaacttgtcagggttagttacaatcacctagctaactcggaggcaggtgcatttctgagaag
cccacccagcctgagcaacagttcatgaaaagctacattgttggagctcttgttctaccaaagagagtttaggaggttggagagtctttttc
agttcagttgactggaaccactgctgggcagctcagctgggaaggtaggttgagtcttttaggcagtgggctggtttctgtctctttagggta
gcttgcttggtctgggtgactttttggaggccttactattcacatacctctaggggagggagggacctagtaaatctggtcagtttcagggac
ttcctaaagctattgagttgttttcttcctgagcttagcttagcaagcaagctttcctactgcttggactgtttcacccctccctgtgtctaaag
gagctttcctccaagatggaaggttttatctggaaggaaatcactaggccataatattggaagggagggaagaggaagaagggagagg
gatgctagggagaggactgaaggaagagaaatccagcaagtttccagtaaacagtttttcctttgtttagcagaccttataatttgctaac
gagtatcttacaagacttcaaaggatgtcatgaggcttgtctgccaagcagctgttttttcttaaactgaacaaaagaaactgcaagagaa
acctcagaccacaggggcttgaagattaggagtgaatgaggtaacagaagatagtgactcttgataccagtcctcatcatgccaattccat
gaactgcttatgacaggtctatggcggtgtagacagcagattttcagaggttccatgttggggcaaatcatgtgaaagtgtgggcactcgg
tgggtttagtgacacagtgaatagagtttttacaaactcgaatgtttgagaaggaggaggaggaggtgggaaggttgctctgacaatcatt
tagtatgagctgtatcagtctctctgatcagatttttttcctttcaaaccacaaacaggatgcagaagacttgtgctgagacaaaaaaaaat
gtttgggtgccagaaacagatcactaaaagagtgtgttttgcatagctttgtcaaagcaggcgaccactttaaaacttgccattttctagttt
taaattcagtcatgacaagcaatacgtccagtgattctttacagatataaacacatgctgagagttggcttgcccatccttttatatgcaggc
attatgagcgaggaaaagggaaaccattttgctaccatttatattatataaattacattaaaatgatgctttttcttatcaagacagataggt
atagtaaatctctagagagcaccccaaactaaaaaaaaaccctcacttttagaactatagccaacattctccatgatatatcatgtactgtt
caatcaacaagcctcagtaaacttgtaaatatcaaataaaaatgaggttttatttatgtaaaaatcttcatggggacatactgaaaagaaa
tctaatttcagtcataaatgagttttaaagatactttcttgtaaggcttaggagatggctcagcaggtgagagtacttgccaccaaagctaa
tgacctgagtttgattctggtaacctacatggtagacaaacagcattgactcctacaagctgtcttctgaccttagcatgcatgccatggtgt
gtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtagacgcagacaaagacacacaagcaaataaacaaacattcttcaacagtttcatattc
caagcgcataatggtatagctattttttggctatctgaagttctgggaaatggagttatgacatctggtaagagccaccaatggtgttagca
tcaacctgccatgtttgtttccatttggggactcgaatgcaaggctaactgcctagcaaattgtttttcatttcctggcgttta 
 
Figure 6. Strategy for generating Il9 ΔCNS-25 mice. (A) Mouse Il9 genomic locus (B) Il9 CNS-25 targeting gRNAs and genotyping primer set for detecting WT allele: Oligo #1 and #2 (C) Mouse Il9 locus after CRISPR/Cas9 mediated gene editing and genotyping primer set for detecting CNS-25 deletion allele: Oligo #1 and  #3 (D) Sequence of mouse Il9 CNS-25 region and sequences of CNS-25 targeting gRNAs. CNS-25 region is marked with yellow highlight and deleted region is marked with red line.  
 
 
 
 
 
D Proximal gRNA 
Distal gRNA 
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Table 1. Sequences of mouse Il9 CNS-25 targeting gRNAs and Il9 ΔCNS-25 mice genotyping 
primers 
 
 
 
In vitro mouse T cell differentiation  
Naïve CD4+CD62L+ T cells from mice were positively selected from the enriched 
CD4+ T cells from spleen and lymph nodes using MACS beads and columns (Miltenyi 
Biotec). Naive CD4+CD62L+ T cells were activated with plate-bound anti-CD3 (2 μg/ml 
145-2C11 ; BioXCell) and soluble anti-CD28 (0.5 μg/ml ; BD Pharmingen) in complete 
culture media, Roswell Park Memorial Institute 1640 (RPMI 1640, ThermoFisher Scientific) 
containing 10% Fetal bovine serum (FBS, Atlanta Biologicals), 1% antibiotics (penicillin 
and streptomycin / stock; Pen 5000 μ/ml, Strep 5000 μg/ml), 1 mM sodium pyruvate, 1 
mM L-Glutamine, 2.5 ml of Non-essential amino acids (Stock; 100 X), 5mM HEPES (all 
from LONZA) and 57.2 μM 2-Mercapoethanol (Sigma-Aldrich), to generate Th0 cells (10 
U hIL-2) or with additional cytokines (all from PeproTech) and antibodies (all from BioXCell) 
to generate Th2 cells (10 ng/ml IL-4; and 10 μg/ml anti-IFN XMG), Th9  cells (20 ng/ml 
CNS-25 mice Protospacer sequence (5’-3’) 
Il9 CNS-25 KO 5’  (Proximal gRNA) CAATCACCTAGCTAACTCGG  Il9 CNS-25 KO 3’  (Distal gRNA) TGCATTCGAGTCCCCAAATG Genotyping primers primer sequence (5’-3’) Program  CNS-25 Primer #1  AAACCATTGTGTGATGTACCTGG  
95°C  5 mins 
95°C  30 sec   X 34 cycle  CNS-25 Primer #2  AAGCCTCATGACATCCTTTGA  
58 °C  30 sec 72 °C   1 min  CNS-25 Primer #3  AACTGACCAGATTTACTAGGTCCC  
72 °C  10 mins 
4 °C  overnight 
29 
IL-4, 2 ng/ml hTGF-β1, 10 μg/ml anti-IFN XMG, 10 μg/ml anti-IL-10 receptor antibody), 
Treg cells (5 ng/ml hTGF-β1, 10U hIL-2, 10 μg/ml anti-IFN,10 μg/ml anti-IL-4), Th17 cells 
(100 ng/ml IL-6, 2 ng/ml hTGF-β1,10 μg/ml anti-IFN,10 μg/ml anti-IL-4) and Th1 cells (20 
ng/ml IL-12, 10 U hIL-2, 10 μg/ml anti-IL-4 11B11) culture conditions. Cells were grown at 
37°C under 5% CO2 and were expanded after 3 days with original concentration of 
cytokines in fresh medium. Cells were harvested on day 4 or 5 for analysis.  
 
Isolation of human PBMCs from buffy coat  
Peripheral blood mononuclear cells (PBMCs) were isolated from human buffy coat 
(Indiana Blood Center, IN) by density gradient centrifugation using Ficoll-Paque (GE 
Healthcare). 15 ml of the buffy coat was diluted with 35 ml of ice cold buffer (PBS with 2 
mM EDTA). 25 ml of this diluted suspension was gently added to 15 ml of Ficoll-paque in 
a 50 ml conical tube. After centrifuging at 400 x g for 40 mins at 20°C, the upper layer was 
gently removed by aspiration. Mononuclear cell layer was transferred to a new 50 ml 
conical tube and filled with buffer up to 50 ml. After mixing, cells were centrifuged at 300 
x g for 10 mins at 20°C. After removing supernatant, cells were resuspended again with 
50 ml of the buffer and centrifuged at 200 x g for 15 mins at 20°C. After repeating this 
washing step, the number of cells were counted and used for the isolation of human naïve 
CD4+ T cells. 
 
In vitro human T cell differentiation 
Human naïve CD4+ T cells were isolated from human PBMCs using magnetic 
separation (Miltenyi Biotec), and these cells were activated with a receptor crosslinking 
bead, Dynabead human T-activator CD3/CD28 (ThermoFisher Scientific) in complete 
media to generate Th0 cells (10 U hIL-2) and Th9 cells (20 ng/ml hIL-4, 2 ng/ml hTGF-β1, 
30 
10 μg/ml anti-IFN). 3 x 105 of naïve CD4+ T cells and an equal ratio of beads in 300 μl of 
culture media were added to 48 well plate. Cells were grown at 37°C under 5% CO2 and 
were expanded after 3 days with original concentration of cytokines in fresh medium. Cells 
were harvested on day 4 or 5 for analysis.  
 
Retrovirus production 
Platinum E cells were grown in 10 ml of Dulbecco’s modified eagle medium 1640 
(DMEM 1640) with 10% FBS and 1% antibiotics in a 100 mm tissue culture dish. When 
confluency reached 80~90%, cells were transfected with control vector or retroviral vector 
containing Etv5, GATA3, E4BP4, BATF, IRF4 open reading frame (ORF) using 
lipofectamine 3000 (ThermoFisher Scientific). For transfection, 18 μg of vector, 6 μg of 
pCL-Eco and 25 μl of P3000 were mixed in 500 μl of Opti-MEM®I reduced-serum medium 
(ThermoFisher Scientific), and 25 μl of lipofectamine 3000 was mixed in another 500 μl of 
Opti-MEM®I. After combining, this mixture was incubated for 10-15 mins at room 
temperature (RT). The mixture was gently pipetted into culture dish. After 16 hours, the 
media containing retrovirus was collected and changed with new fresh media. After 24 
hours, the media was collected and centrifuged at 1500 rpm for 5 mins to remove cell 
debris. Supernatant containing retrovirus was used for retroviral transduction or stored at 
-80 °C for subsequent use.   
 
Retroviral transduction 
Activated mouse CD4+ T cells were infected on day 1 with retrovirus containing 
control or expressing the interested gene by centrifugation at 2300 rpm at 32oC for 90 
mins in the presence of 8 μg/ml polybrene (Sigma-Aldrich). After spin infection, the 
supernatant was replaced with the fresh Th cell condition media. Cells were expanded on 
day 3 and analyzed on day 4 or 5.  
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CRISPR /Cas9 plasmid construct 
PX330A_D10A-1X2 (Addgene #58772) was modified by adding ClaI site in front 
of hU6 promoter, termed as ‘new pX330A_D10A-1X2’. gRNAs were designed using Feng 
Zhang lab’s online tool (http://crispr.mit.edu/). After annealing of gRNA oligos, the gRNAs 
duplexes were cloned to new pX330A_D10A-1X2 and pX330S-2 (Addgene #58778) using 
BbsI (BpiI) (Table 2). Through Golden gate assembly using Eco31I, new pX330A_D10A-
1X2 which contains gRNA cassette containing two hU6 promoter and two gRNAs was 
made. By using Cla1 and Kpn1, the gRNA cassette from this vector was inserted to new 
lentiCRISPR v2 (modified from lentiCRISPR v2,  Addgene #52961, by adding new cloning 
site containing Cla1 and Kpn1) using Cla1 and Kpn1. Finally, DNA element containing 
gRNA cassette of this new lentiCRISPR v2 was replaced with lentiCas9-EGFP (Addgene 
#63592) using Not1 and Nhe1 (Figure 7). Plasmids and gRNA sequences are listed in 
Table 2 and 3.  
 
Table 2. CRISPR/Cas9 plasmids 
Construct Oligo Overhang Protospacer Overhang New PX330A_D10A 1X2 
sgRNA-1 sense 5’-CACCG (N)20  sgRNA-1 antisense 3’-C (N)20 complement CAAA-5’  PX330S_2  
sgRNA-1 sense 5’-CACCG (N)20  sgRNA-1 antisense 3’-C (N)20 complement CAAA-5’  
Table 3. Sequences of gRNAs targeting hIL9 CNS-18 and GM38602 
 gRNAs  Target location 
 Protospacer sequence (5’-3’)  Genome 
hIL9 CNS-18 5A CNS-18 CAGAGTAGATCTTCCATTGG Human hIL9 CNS-18 3A CNS-18 AGAGATGGGGTCTCCCTATG Human mGM38602 5A GM38602 GCCCGGGCTCGATCTATTAA Mice mGM38602 3A GM38602 CCTCTCCAGGTGTTAACTAC Mice 
32 
 
 
Figure 7. Single lentiviral vector expressing Cas9 and gRNAs. (A) Simplified map and (B) full map for vector 
 
 
 
Lentivirus production 
Human embryonic kidney (HEK) 293T cells were grown with 10 ml of DMEM 1640 
with 10% FBS and 1% antibiotics in a 100 mm tissue culture dish. When confluency 
reached 95~99%, cells were transfected with lentiviral vectors expressing Cas9 and 
gRNAs targeting hIL9 CNS-18 or GM38602 as a negative control using lipofectamine 3000. 
For transfection, 10 μg of lentiviral vector, 8 μg of PAX2, 5 μg of PMDG.2 and 40 μl of 
A
BIl
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P3000 were mixed in 1,500 μl of Opti-MEM®I, and 40 μl of lipofectamine 3000 was mixed 
in another 1,500 μl of Opti-MEM®I. After combining, these mixtures were incubated for 10-
15 mins at RT, and gently pipetted into culture dish. After 6 hours, media was changed to 
the lentivirus packaging media; Opti-MEM®I-GlutaMAX (ThermoFisher Scientific) with 5% 
FBS and 0.2 mM sodium pyruvate, and incubated another 16 hours. The first batch of 
virus was harvested, and fresh lentivirus packaging media was added. After 24 hours, the 
second batch of virus was collected and combined with the first batch of virus. After filtering 
media containing lentivirus using a 0.45 µm filter, Lenti-X-concentrator (Takara) was 
added 1:3 volume and incubated at 4°C overnight with rotation. The following day, the 
mixture was centrifuged at 1,500 x g for 45 mins at 4°C. The pellet was resuspended in 
500 μl of PBS, aliquoted to 100 μl, and stored at -80 °C for future use.  
 
Lentiviral infection 
Sterile non-tissue-culture treated 24 well plates were coated with 50 μg/ml of 
Retronectin (Takara) and incubate at 4°C overnight. The next day, after washing the plate 
with PBS, blocking buffer (PBS with 2% bovine serum albumin (BSA)) was added and 
incubated at RT for 30 mins. After removing the buffer, lentivirus stock (100μl) and 500 μl 
of culture media was added to the plate. After loading lentivirus to the plate using 
centrifugation with 2000 x g at 32°C for 2 hours, day 1 cultured human T cells were 
transferred to the plate and incubated for 2~3 days. Cells were harvested on day 4 or 5 
for analysis using flow cytometry or sorted by fluorescence activated cell sorter (FACS; 
BD FACSAria) based on EGFP for gene expression analysis.  
 
Aspergillus fumigatus extract-induced allergic airway inflammation  
Mice were challenged intranasally with Aspergillus fumigatus (A.fumigatus; Greer 
Laboratories) extract every other day for 21 days. A. fumigatus (25-100μg) extract was 
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diluted with PBS (20-50 µl) and administered into the nose. Mice were sacrificed 1 day 
after final intranasal challenge. Bronchoalveolar lavage (BAL) cells were collected by 
lavaging the lungs with 1 ml PBS. To prepare single cell suspension from lungs, lung 
tissues were chopped and incubated with 0.5 mg/ml of collagenase A (Roche) in DMEM 
at 37°C for 45 mins. After grinding tissues with mesh stainless steel strainer, red blood 
cells were removed by Ammonium-Chloride-Potassium (ACK) lysing buffer (LONZA). 
After stopping the reaction by adding buffer (PBS with 0.5 % BSA), cells were washed 
with the buffer followed by filtering through 70 μm nylon mesh to remove debris. Single 
cell suspensions were stimulated with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin for 6 hours to assess cytokine production using intracellular staining. Cytokines 
in BALF were measured by enzyme linked immunosorbent assay (ELISA). 
 
House dust mite extract-induced allergic airway inflammation 
Mice were challenged intranasally with house dust mite (HDM; Greer Laboratories) 
extract every other day for 16 days. HDM extract (25 μg) was diluted with 20 µl PBS and 
administered into the nose. Mice were sacrificed 1 day after final intranasal challenge. The 
subsequent procedures for sample harvesting are the same as for the A. fumigatus 
extract-induced allergic airway inflammation experiment.  
 
Reverse transcription (RT) and quantitative real-time PCR (qPCR) 
Total RNA was extracted using TRIzol reagent (ThermoFisher Scientific) and 
reverse transcribed using cloned Avian Myeloblastosis Virus (AMV) reverse transcriptase 
(ThermoFisher Scientific). For qPCR, Taqman real time PCR assay (ThermoFisher 
Scientific) was used for gene expression analysis. Taqman probes used for qPCR are 
listed in Table 4. Gene expression was normalized to housekeeping gene expression (2-
microglobulin). The relative gene expression was calculated by the change-in-threshold 
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(2^-CT) method. All experiments were performed in duplicate in two independent 
experiments and results are presented as standard error of means (SEM) of biological 
replicates.  
                    Table 4. Taqman probes for qPCR 
Mouse Gene Cat. No. β2m Mm00437762_m1 Batf Mm00479410_m1 Bcl6 Mm00477633_m1 Jun Mm00495062_s1 Foxp3 Mm00475165_m1 Gata3 Mm00484683_m1 Id3 Mm00492575_m1 Ifng Mm01168134_m1 Il9 Mm00434305_m1 Il10 Mm00439614_m1 Il17a Mm00439618_m1 Il4 Mm00445259_m1 Irf1 Mm00515191_m1 Irf4 Mm00516431_m1 Junb Mm04243546_s1 Nfil3 Mm00600292_s1 Rorc Mm00441139_m1 Runx3 Mm00490666_m1 Spi1 Mm00488142_m1 Stat6 Mm01160477_m1 Tbx21 Mm00450960_m1 Human Gene Cat. No. B2M Hs99999907_m1 IL10 Hs99999035_m1 IL21 Hs00222327_m1 IL9 Hs00914237_m1 STAT6 Hs00598625_m1  
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Flow cytometric analysis 
For cytokine staining, in vitro cultured CD4+ T cells were stimulated with PMA and 
ionomycin for 2 hours followed by monensin for a total of 6 hours. After fixation with 1% 
formaldehyde for 10 mins at RT, cells were washed two times with FACS buffer (PBS with 
0.5 % BSA). For transcription factor staining, cells were fixed with Foxp3/Transcription 
factor fixation buffer (eBioscience) at 4°C in dark for 30 mins or overnight. Fixed cells were 
permeabilized with permeabilization buffer (eBioscience), and stained for cytokines and 
TFs with fluorochrome conjugated antibodies at 4°C in dark for one hour. Stained cells 
were washed two times with FACS buffer and resuspended with 500 μl of FACS buffer for 
flow analysis. Fluorescent antibodies for flow cytometric analysis are listed in Table 5. 
 
Table 5. Fluorescent antibodies for flow cytometric analysis 
Antigen/Name Clone Fluorochrome Company Cat. No. CD11b M1/70 PerCP-Cy5.5 eBioscience 45-0112-82 CD11c N418 PE-Cy7 eBioscience 25-0114-82 CD3 145-2C11 PerCP-Cy5.5 BD Biosciences 551163 
CD4 
GK1.5 FITC BD Biosciences 553729 GK1.5 PE BioLegend 100408 GK1.5 PerCP-Cy5.5 BioLegend 100434 GK1.5 PE-Cy7 BioLegend 100422 GK1.5 APC BioLegend 100412 GK1.5 APC-Cy7 BD Biosciences 552051 F4/80 BM8 FITC BioLegend 123108 Foxp3 MF23 FITC BD Biosciences 560403 IFN-γ XMG 1.2 PerCP-Cy5.5 eBioscience 45-7311-82 
IL-10 JES5-16E3 FITC BioLegend 505006 JES5-16E3 PE eBioscience 12-7101-82 IL-17A eBio17B7 PE-Cy7 eBioscience 25-7177-82 IL-4 11B11 AF647 BioLegend 504110 IL-9 RM9A4 PE BioLegend 514104 Ly6G 1A8 APC BioLegend 127613 SiglecF E50-2440 PE BD Biosciences 552126 Fixable Viability dye  eFluor 780 eBioscience 65-0865-14  
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Enzyme linked immunosorbent assay (ELISA) 
Cytokine capturing antibodies were coated on 96 well plate (NUNC) with 50 μl of 
coating buffer (dH2O with 0.1 M NaHCO3 pH 9) and incubated at 4°C overnight. After 
washing the plate three times with washing buffer (PBS with 0.05% Tween-20), 250 μl of 
ELISA buffer (PBS with 2% BSA) was added to well and incubated at RT for one hour to 
prevent non-specific binding. After washing the plate three times with washing buffer, 100 
μl of diluted samples (10-100 fold diluted with ELISA buffer) and standard cytokines were 
added and incubated at 4°C overnight. The next day, after washing the plate three times 
with washing buffer, 100 μl of the biotinylated secondary antibody was added and 
incubated at RT for one hour. After washing the plate three times with washing buffer, 100 
μl of washing buffer with 0.05% of avidin-alkaline phosphatase (Sigma-Aldrich) was added 
and incubated at RT for one hour. After washing the plate three times with washing buffer, 
100 μl of the substrate buffer with p-Nitrophenyl Phosphate (PNPP) (Sigma-Aldrich), a 
phosphatase substrate, was added to each well. Reaction was stopped by adding stop 
solution (1N NaOH) and measured with the Biorad Microplate 680 ELISA reader. Primary 
and secondary antibodies for ELISA are listed in Table 6. 
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Table 6. ELISA capture and biotinylated secondary antibodies  
Capture Abs Clone Stock Final conc. Company Cat. No. IL-17A TC11-18H10 0.5mg/ml 2ug/ml BD Biosciences 555068 IL-10 JES5-2A5 1mg/ml 4ug/ml BD Biosciences 551215 IL-4 11B11 0.5mg/ml 2ug/ml BD Biosciences 554434 IL-9 D8402E8 1mg/ml 1ug/ml BD Biosciences 551218 IFN-γ R4-6A2 1mg/ml 2ug/ml BD Biosciences 551216 Secondary Abs Clone Stock Final conc. Company Cat. No. IL-17A TC11-18H10 0.5mg/ml 1ug/ml BD Biosciences 555067 IL-10 SXC-1 0.5mg/ml 1ug/ml BD Biosciences 554423 IL-4 BVD6-24G2 0.5mg/ml 1ug/ml BD Biosciences 554390 IL-9 D9302C12 0.5mg/ml 1ug/ml BioLegend 504804 IFN-γ XMG1.2 0.5mg/ml 1ug/ml BD Biosciences 554410  
 
 
Chromatin Immunoprecipitation (ChIP) 
In vitro differentiated Th cells (1 x 107) were cross-linked for 15 mins with 1% 
formaldehyde at RT with rotation. The reaction was quenched by adding 0.125 M glycine 
and incubated at RT for 5 mins.  Cells were washed with ice cold PBS two times. After the 
second wash, cell pellets were processed for next step or stored at -80 °C for subsequent 
use. Fixed cells were lysed by 400 μl of cell lysis buffer and incubated on ice for 10 mins. 
After centrifugation, supernatant was discarded and lysates were incubated with 400 μl of 
nuclear lysis buffer on ice for 10 mins.  Nuclei were degraded and chromosomal DNA 
were fragmented by sonication using sonicator. After sonication, debris were removed by 
centrifugation at 13000 rpm for 10 mins at 4°C and supernatant was transferred to new 
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tube. 40 μl of supernatant containing lysates of 1 x 106 cells was used for one ChIP 
experiment. The supernatant was diluted 10 fold with ChIP dilution buffer. After pre-
clearing with salmon sperm DNA, bovine serum albumin, and a protein agarose A bead 
slurry (50%, Millipore), the supernatant was incubated with the ChIP antibodies for either 
rabbit polyclonal Etv5, p300, E4BP4, IRF4, STAT6, STAT5 (Santa Cruz Biotechnology), 
GATA3, IRF4 D9P5H, BATF D7C5, PU.1 (Cell Signaling Technology), SMC1 or 
CRSP1/TRAP220 (Bethyl Laboratory), H3K14ac or normal rabbit IgG (Millipore), 
H3K4me1, H3K27ac, H3K4me3 or H3K27me3 (Abcam) at 4oC overnight with rotation. 
ChIP antibodies are listed in Table 7. The following day, immunocomplexes containing 
antibody/protein/DNA were incubated with Protein Agarose A or G beads at 4oC for 2~4 
hours. After centrifuging at 2000 rpm for 2 mins at 4°C, the supernatant of the IgG control 
sample was kept for input samples. Immunocomplexes were washed one time with low 
salt, high salt, LiCl and two times with TE buffer. After the last wash of TE buffer, 
complexes were incubated with 250 μl of elution buffer at RT for 15 mins with rotation. 
After centrifuging at 2000 rpm for 2 mins at RT, the supernatant was transferred to new 
fresh tube. After repeating the elution step, 25 μl of 4M NaCl was added to 500 μl of 
supernatant to reverse cross-links at 65oC overnight. The next day, DNA was purified 
using phenol-chloroform extraction, and resuspended in 200 μl of nuclease free water and 
analyzed by qPCR. SYBR green master mix (Applied Biosystems) was used to measure 
amplification of DNA using 7500 Fast Real-Time PCR system (Applied Biosystems). ChIP 
primer sequences are listed in Table 8. After normalization to the Input DNA, the amount 
of output DNA of each target protein was calculated by subtracting that of the IgG control.  
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Table 7. Antibodies for ChIP assay 
Transcription factor Antigen/Name Clone Host Company Cat. No. 
BATF D7C5 Rabbit Cell Signaling Technology 8638 
C-Jun H-79 Rabbit Santa Cruz Biotechnology sc-1694 CRSP1/TRAP220 polyclonal Rabbit Bethyl Laboratories A300-793A 
CTCF D31H2 Rabbit Cell Signaling Technology 3418 
E4BP4 C-18 Goat 
Santa Cruz Biotechnology Sc-9550 
V-19 Goat Santa Cruz Biotechnology Sc-9549 
ETV5 H-100 Rabbit Santa Cruz Biotechnology Sc-22807 
GATA3 D13C9 Rabbit Cell Signaling Technology Sc-268 
GCN5 H-75 Rabbit Santa Cruz Biotechnology Sc-20698 
IRF4 D9P5H Rabbit 
Cell Signaling Technology 15106 
H-140 Rabbit Santa Cruz Biotechnology Sc-28696 
Jun-B 210 Rabbit Santa Cruz Biotechnology Sc-73 
P300 N-15 Rabbit Santa Cruz Biotechnology Sc-584 
PU.1 9G7 Rabbit Cell Signaling Technology 2258 SMC1 polyclonal Rabbit Bethyl Laboratories A300-055A 
STAT5 C-17 Rabbit Santa Cruz Biotechnology Sc-835 
STAT6 M-20 Rabbit Santa Cruz Biotechnology Sc-981 Histone modification Antigen/Name Clone Host Company Cat. No. H3ac polyclonal Rabbit Millipore 06-755 H3K27ac polyclonal Rabbit Abcam Ab4729 H3K27me3 mAbcam6002 mouse Abcam Ab6002 H3K4me1 polyclonal Rabbit Abcam Ab8895 H3K4me3 polyclonal Rabbit Abcam Ab8580 H4K16ac polyclonal Rabbit Millipore 07-329 H4K5ac monoclonal Rabbit Millipore 04-118 H4K5ac monoclonal Rabbit Millipore 04-118 H4K8ac polyclonal Rabbit Millipore 07-328 
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Normal Rabbit IgG polyclonal Rabbit Millipore 12-370  
Table 8. Sequences of ChIP primers 
Mouse Primers Forward (5'-3') Reverse (5'-3') Il9 CNS-6 GAGCTGAACGCAGGCCAAGAACGA CTTGGAACTAGTTATCTCTCCACTG -6 kb Il9 promoter GTGGGCACTGGGTATCAGTTTGATGT CAGTCTACCAGCATCTTCCAGTCTAG -5bp ~ -67bp  Il9 CNS -25_1 ATGTCATGAGGCTTGTCTGC ACTCCTAATCTTCAAGCCCCT Il9 CNS -25_2 AGCAGGCGACCACTTTAAAA GCCAACTCTCAGCATGTGTT 
Il9 -35 kb GAGGGAGAGGGGAAAACACA TACCGCTCCGCAGTCTAAAT Il9 -12 kb GTTGCCTTGGTTATGGTGCT AGAATGGCCCATGAAGACCA 
Human 
Primers Forward (5'-3') Reverse (5'-3') hIL9 CNS-4.5 GTCACCTCACCTGTCTCCTT ACATTGGTGCAGGGTTTGAG hIL9 promoter AAGTGGCCCCAACTTACAGA CGCTTGCAGACACCTTCAAA hIL9 CNS -18_1 ACCTAGCCCACTGTGCAACT CATGATGACCCTGTGGTCTG 
hIL9 CNS -18_2 TTTCAGAGTCAGAAGAAAAGATGG CATTTAGGGTGTTGCCTTTCA 
hIL9 -30 kb AGACCAAGGACGTTAGAGCA GTTGCCATTTTAGCTAGCTTTGG hIL9 -12 kb CTGGGCTCTTTGGAGAAATG CAATGTGGCTTTTGGGATTT  
 
 
Luciferase reporter assay 
HEK 293T cells were grown in DMEM 1640 with 10% FBS and 1% antibiotics in a 
12 well plate. When confluency reached 80~90%, cells were co-transfected with 1 μg of 
the Il10 promoter or CNS3 luciferase reporter vector (pGL3 basic) and 1 μg control or Etv5 
expressing vector (pcDNA3.1) and 0.5 μg of pRL-TK for endogenous control using 
lipofectamine 2000 (ThermoFisher Scientific).  
EL4 cells, mouse lymphoma cell line, were grown in RPMI 1640 with 10% FBS 
and 1% antibiotics in a 12 well plate. 2 x 106 cells were co-tranfected with 5 μg of the Il9 
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gene locus containing pGL3 basic vector and 5 μg control or interested gene expressing 
pcDNA3.1 vector and 0.5 μg of pRL-TK for endogenous control using Amaxa 
Nucleofection Kit L (Lonza).  
After 24 hours of transfection, cells were stimulated with PMA/ionomycin (only for 
EL4 cells) for 6 hours and washed with PBS two times. After the second wash, cells were 
lysed through 250 μl of passive lysis buffer followed by sonication. After centrifugation at 
14000 rpm for 1 min at 4°C, supernatant was transferred to new tube to assess luciferase 
activities. Luciferase activities were measured using the dual luciferase reporter assay 
system (Promega) according to the manufacturer’s instructions. Firefly values were 
normalized to renilla values; Firefly values from luciferase reporter vectors, renilla values 
from pRL-TK 
 
Statistical analysis 
Two tailed Student’s t-test or one-way analysis of variance (ANOVA) were used to 
generate p-value data for all data.  Post hoc Tukey test was used for multiple comparisons. 
p ≤ 0.05 was considered statistically significant. 
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RESULTS 
Part I. The ETS family transcription factors Etv5 and PU.1 function in parallel to 
promote Th9 cell development 
 
Etv5 promotes IL-9 production  
A recent report demonstrated that Etv5 promotes IL-17 production and is induced 
in response to STAT-activating cytokines (107). However, Etv5 had limited functions in 
Th1 cells and seemed to repress IL-4 production. The repression of IL-4 was reminiscent 
of the phenotype observed in T cells that lack PU.1 expression (158). Thus, we were 
interested in determining the effects of Etv5 on Th9 development. To test this, we isolated 
naive T cells from Etv5fl/fl mice that were either negative or positive for CD4-Cre (referred 
to in the figures as Etv5 ΔCD4) and cultured them under Th2 or Th9 skewing conditions. By 
intracellular cytokine staining, we observed a diminished percentage of IL-9–producing 
cells in Th2 and Th9 cultures lacking the expression of Etv5 (Figure 8A). We also observed 
an increased percentage of IL-4+ cells in Th2 and Th9 cultures lacking Etv5 (Figure 8A). 
This observation was consistent with decreased IL-9 and increased IL-4 in the 
supernatants of Etv5-deficient Th2 and Th9 cultures, and with mRNA expression of these 
cytokines (Figure 8B, 8C). We further observed that Th2 cytokines, including IL-5 and IL-
13, were increased in the absence of Etv5 (Figure 8B). To directly demonstrate the 
function of Etv5, we transduced developing Th9 cells with retroviruses containing either 
no cDNA or expressing Etv5. Ectopic expression of Etv5 in Th9 cells increased the 
production of IL-9 and further decreased the minimal production of IL-4 (Figure 8D). 
Similarly, ectopic expression of Etv5 in Th2 cells repressed IL-4 production and increased 
the percentage of cells positive for IL-9 (Figure 8D). Thus, Etv5 regulates production of IL-
9.  
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Figure 8. Etv5 promotes IL-9 and inhibitsTh2-associated cytokine production. (A–D) Wild type or Etv5 ΔCD4 naive CD4+T cells were cultured in vitro under Th2 or Th9 conditions for 5 days. (A) Representative FACS profiles of IL-9–and IL-4–producing cells after stimulation with PMA/ionomycin for 6 hours. Depicted cells were gated as FSCloSSCloCD4+. (B) Cytokines secreted after stimulation with anti-CD3 for 24 hours. (C) Il9 and Il4 expression after stimulation with anti-CD3 for 6 hours. Data were normalized to β2m expression. Il9 expression was relative to wild type Th2, and Il4 was relative to wild type Th9. (D) Wild type naive CD4+T cells were cultured for 5 days in Th9 condition and were transduced with control or Etv5-expressing retrovirus on day 2 of culture. Representative FACS profiles of IL-9–and IL-4–producing transduced cells. Cells were stimulated with PMA/ionomycin. Depicted cells were gated as FSCloSSCloCD4+Thy1.1+. Data are represented as mean ± SEM. (A–C) Data depicted are from two independent experiments (four to five mice per experiment) (D) Data depicted are from three independent experiments (two mice per experiment). A two-tailed Student t test was used for pairwise comparisons. *p< 0.05, **p<0.01. 
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Etv5 gene expression is induced after T cell activation. We compared the 
expression of Etv5 during the development of Th2, Th9, and inducible Treg cells, and 
observed that although there is no induction of Etv5 during Treg development, Etv5 is 
dynamically regulated in Th2 and Th9 cells (Figure 9A). We observed a rapid increase in 
Th2 cells and a slower increase in Th9 cells that ultimately fell to similar levels after 5 days 
in culture (Figure 9A, 9B). After stimulation of Th9 cells after 5 days of culture, Etv5 mRNA 
is rapidly induced by 4 hours (Figure 9C). Consistent with regulation dissimilar from Sfpi1, 
we observed Etv5 mRNA was dependent on STAT6 (Figure 9D). Etv5 mRNA was also 
decreased in Th9 cultures by the absence of IRF4, suggesting Etv5 expression is 
downstream of a STAT6/IRF4 network. In contrast, Etv5 expression was increased in Th9 
cultures that lacked the expression of BATF or PU.1, suggesting that IL-4–dependent 
expression does not require BATF (Figure 9D). 
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Figure 9. Etv5 expression in Th cell subsets. (A–C) Wild type naive CD4+T cells were cultured in vitro under Treg, Th2, or Th9 conditions for 5 days. (A) Every 24 hours during the culture period, RNA was isolated to assay for Etv5 expression by qRT-PCR in each culture condition. (B) Comparison of Etv5 expression among the subsets at day 5 of culture. (C) Etv5 mRNA levels in Th9 cells activated with anti-CD3 for the indicated time points. (D) T cells from mice of the indicated genotypes were cultured in vitro under Th9 condition over 5 days. Etv5 expression was measured using qRT-PCR at day 5 of culture. A two-tailed Student t test was used for pairwise comparisons. *p< 0.05, **p<0.01. (A–D) Data are represented as mean ± SEM from at least two independent experiments. 
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Chromatin remodeling at the Il9 locus by Etv5  
Previous reports indicated that PU.1 bound to the Il9 promoter and recruited Gcn5-
containing complexes to alter the histone modifications at the Il9 locus (59, 101). We first 
tested whether Etv5 also binds to the Il9 locus at three CNS regions: CNS-6, CNS1 (Il9 
promoter), and CNS+5.5 (155). Etv5 binding was significantly enriched at the CNS-6 and 
CNS+5.5 regions (Figure 10A). This was in contrast with PU.1 binding that is enriched 
primarily at the Il9 promoter (59, 90). Moreover, Etv5 binding at CNS+5.5 was significantly 
greater in Th9 cells than in either Th2 or Th17 cells, and binding at CNS-6 was significantly 
greater in Th9 than Th17, with a trend toward increased binding compared with Th2 cells 
(Figure 10B). The binding of Etv5 to a nonconserved sequence in the Il9 locus was barely 
detectable (Figure 10B). PU.1 and Etv5 also had differential effects on the recruitment of 
HAT proteins to the locus. In contrast with PU.1-deficient Th9 cells that had increased 
p300 association and decreased Gcn5 association with the Il9 locus (101), Etv5-deficient 
cells had normal Gcn5 recruitment but significantly decreased p300 recruitment, 
correlating with significant decreases in the overall histone H3 acetylation and H4K16 
acetylation at the Il9 promoter (Figure 10E, 10F). The histone acetylation events were 
specific because there was no difference in the acetylation of H4K5 or H4K8 between 
control and Etv5- deficient Th9 cells (Figure 10G, 10H). These results suggest that 
although PU.1 and Etv5 have overlapping biological functions, they promote the 
expression of Il9 by acting on the Il9 locus through distinct binding sites. 
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Figure 10. Etv5 binds and enhances histone acetylation at the Il9 locus (A–H) Wild type or Etv5 ΔCD4 naive CD4+T cells were cultured in vitro under Th9 condition, unless depicted otherwise, for 5 days. (A) Etv5 binding, with respective isotype controls, at the Il9 locus. (B) Etv5 binding within indicated Th cultured cells at the Il9 locus and a -12 kb region of the Il9 locus (negative control). (C and D) p300 or GCN5 binding to the Il9 promoter. (E–H) Depicted histone acetylation levels at the Il9 promoter. (B–H) Percent input depicted are the Etv5 ChIP values after subtraction of the control Ig ChIP values. Data are represented as mean ± SEM from two to three independent experiments (three mice per experiment). A two-tailed Student t test was used for pairwise comparisons. One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. *p<0.05, **p<0.01, ***p<0.001. 
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Parallel effects of PU.1 and Etv5 in vitro  
These results suggested that Etv5 has distinct and overlapping functions with PU.1 
in the development of Th9 cells. To test this directly, we mated mice with a conditional 
PU.1-expressing allele (Sfpi1 fl/fl) with the Etv5fl/fl mice, in the context of the CD4-Cre 
transgene. Naive CD4+ T cells were isolated from control, Etv5fl/fl CD4-Cre, Sfpi1fl/fl CD4-
Cre, and Sfpi1 fl/fl/Etv5fl/fl CD4-Cre mice, and cultured under Th9 conditions. Consistent 
with our previous reports, Th9 cultures that were deficient in PU.1 had diminished IL-9 
production (Figure 11). Similarly decreased levels of IL-9 were observed in Etv5-deficient 
Th9 cultures. Importantly, Th9 cultures that were doubly deficient in PU.1 and Etv5 
showed an additive effect of the deletion of each gene and had the lowest percentages of 
IL-9 producing Th cells. Interestingly, although deficiency in either PU.1 or Etv5 increases 
the production of IL-4, there was not an additive effect of deficiency in both factors, with 
double-deficient Th9 cultures having intermediate percentages of IL-4 producing Th cells. 
 
 
Figure 11. Effect of deficiency in Etv5 and Sfpi1 on Th9 differentiation. Wild type, Etv5 ΔCD4, Sfpi1 ΔCD4, or Etv5/Sfpi1 ΔCD4 naive CD4+ T cells were cultured in vitro under Th9 condition for 5 days. Representative FACS profiles of IL-9– and IL-4–producing cells. Cells were stimulated with PMA/ionomycin. Depicted cells were gated as FSCloSSCloCD4+. Data are represented as mean ± SEM from three independent experiments (two to three mice per experiment). One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. *p<0.05, **p<0.01, ***p<0.001. Experiments performed in collaboration with Dr. Matthew Hufford. 
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Parallel effects of PU.1 and Etv5 in vivo  
We then tested whether combined deficiency in PU.1 and Etv5 had distinct effects 
on IL-9 production when tested in vivo. We used the OVA/Alum allergic airway 
inflammation model that has previously been shown to be partially dependent on IL-9 and 
PU.1 expression in Th cells (59). Mice were sensitized and challenged as portrayed in 
Figure 12A. Overall, we observed that there were parallel effects of deficiency in both PU.1 
and Etv5 in Th cells, with each affecting distinct aspects of inflammation. We observed 
that PU.1 alone had a greater effect on total inflammation as assessed by histology and 
eosinophils in the lung (Figure 12B, 12D, 12H). Etv5 deficiency resulted in significant 
decreases in mucus production, polymorphonuclear leukocytes (PMNs) infiltration, and 
mast cell accumulation (Figure 12C, 12F, 12H, 12I). Among these parameters, the double-
deficient mice were not significantly different from the respective single-deficient mice, 
suggesting that PU.1 and Etv5 were controlling separate aspects of inflammation. 
However, only the double-deficient mice were significantly lower than wild type mice in 
total lung cell accumulation, Muc5ac expression, and Mcpt2 expression (Figure 12E, 12G, 
12J). Moreover, double-deficient mice demonstrated Mcpt1 expression that was 
significantly lower than wild type and either of the single-deficient mice (Figure 12J).  
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Figure 12. Pathology of mice deficient in both Etv5 and Sfpi1 in an allergic disease model. (A) Schematic of OVA/Alum model used to promote allergic inflammation. Unchallenged mice were sensitized with OVA/Alum but did not receive OVA challenge intranasally. Representative images of H&E (B) and PAS staining (C) of inflamed lung tissue. (D) Tabulated pathology scores from H&E-stained tissues. (E) Absolute cell numbers of the lungs. (F) Tabulated PAS scores. (G) Muc5ac expression in the lung. Data were normalized to β2m expression. (H–I) Eosinophil (FSCloSSCint/hiSigLecF+CD11c-), neutrophil (FSCloSSCintLy6G+CD11bhi), and mast cell (FSCintSSCintFcεR1+cKit+) absolute numbers in the lung. (J) Mcpt1 and Mcpt2 expression in the lung. Data were normalized to β2m expression. (D–J) Data represented as mean ± SEM from two independent experiments (five to six mice per treatment per experiment). One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. *p<0.05, **p<0.01, ***p<0.001. Experiments performed in collaboration with Dr. Matthew Hufford. 
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We then tested whether this corresponded to decreased IL-9 production in vivo. 
Although there was a similar reduction in total CD4+ T cells in the lung in each single- or 
double-deficient mouse (Figure 13A), there was an overall decrease in the number and 
percentage of IL-9 producing Th cells in the lung, with T cells from double-deficient mice 
demonstrating IL-9 reduced to background amounts (Figure 13B, 13C), although these 
values were not significantly decreased compared to mice with PU.1-deficient Th cells. 
This is in contrast with the numbers and percentages of lung Th2 cytokine–producing Th 
cells that were, respectively, modestly decreased or unaffected (Figure 13B, 13C). The 
number of IL-13– producing Th cells in the lung was decreased in double-deficient mice, 
although the percentages in the lung were not decreased, suggesting a link to overall 
inflammation (Figure 12). Moreover, in the periphery, Th2 responses developed normally. 
OVA stimulation of draining lymph node cells yielded normal or slightly increased 
production of Th2 cytokines (Figure 13D). This was in contrast with OVA-stimulated IL-9 
concentrations that were significantly decreased in cultures from mice with PU.1-deficient 
or double deficient T cells (Figure 13D). Together, these data demonstrate a role for Etv5 
in regulating IL-9 production and Th9 development in vitro and regulating allergic 
inflammation in parallel with PU.1. 
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Figure 13. CD4+ T cell responses in Etv5- and Sfpi1-deficient mice during allergic inflammation. Pulmonary allergic inflammation was generated as in Figure 12. (A) Absolute number of CD4+ T cells (FSCloSSCloCD3ε+CD4+CD8-) in the lung. Numbers (B) and percentage (C) of cytokine producing CD4+ T cells in the lung. (D) Cells were collected from the lung draining lymph nodes in allergic mice. Equivalent numbers of cells were cultured with exogenous Ova for 36 hours. Supernatant was analyzed for depicted cytokines. Data are represented as mean ± SEM from two independent experiments (five to six mice per treatment per experiment). One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. *p<0.05, **p<0.01, ***p<0.001. Experiments performed in collaboration with Dr. Matthew Hufford. 
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Part II. Etv5 regulates IL-10 production in Th cells 
 
Etv5 promotes lL-10 production in Th1 and Th2 cells 
Our previous studies have demonstrated that Etv5 promotes the production of IL-
17A, IL-17F, and IL-21 in Th17 cells, while it had a modest repressive effect on Th2 
cytokines (107). Interestingly, a recent study showed that Etv5 is highly expressed in IL-
10-producing Th1 cells (159). To determine if Etv5 had a role in regulating IL-10 production, 
we isolated naïve CD4+ T cells from Etv5fl/fl CD4-Cre mice and Cre-negative littermate 
control and cultured them under Th1 and Th2 cell polarizing conditions before measuring 
IFN-γ, IL-4 and IL-10 production using intracellular cytokine staining. Although total IFN-
γ-producing Th1 cells or IL-4-producing Th2 cell populations were not affected by Etv5 
deficiency, we observed a significant decrease in IL-10-producing Th1 and Th2 cells in 
the absence of Etv5 (Figure 14A-D). Consistent with these results, Il10 gene expression 
and secreted IL-10 concentrations were significantly decreased in Etv5 deficient Th1 and 
Th2 cells (Figure 14C &D). To further test the function of Etv5, we introduced Etv5 into 
Th1 and Th2 cells using retroviral transduction. Ectopic expression of Etv5 strongly 
enhanced IL-10 production in both Th1 and Th2 cells (Figure 14E). However, the total 
number of Th1 or Th2 cells were not affected (data not shown). Taken together, these 
data suggested that Etv5 positively regulates IL-10 production in both Th1 and Th2 cells 
without affecting lineage specific cytokine production.  
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Figure 14. Etv5 promotes IL-10 but does not affect IL-4 and IFN-γ production. 
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Figure 14. Etv5 promotes IL-10 but does not affect IL-4 and IFN-γ production. (A-D) Naïve CD4+ T cells from control and Etv5fl/fl CD4 Cre+ mice were cultured under Th1 or Th2 cell conditions for 5 days. (A) On day 5, Th1 and Th2 cells were stimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. (B) Average percentage of IL-10-producing Th1 and Th2 cells. (C-D) Th1 and Th2 cells were restimulated with anti-CD3 for 6 hours or overnight to measure Il10 gene expression by using qRT-PCR (C) or to assess cytokine production by means of ELISA (D). (E) Naïve CD4+ T cells from wild type mice were differentiated under Th1 and Th2 cell conditions. Twenty four hours after initiation of culture, cells were transduced with control or Etv5 expressing retrovirus. On day 5, cells were stimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. Data are mean ± SEM of 4 mice per group and representative of three independent experiments. A two-tailed Student t test was used for pairwise comparisons. *p < 0.05, **p <0.005. 
 
 
 
Etv5 regulates IL-10 production in vivo 
A. fumigatus-challenged Il10-/- mice showed exaggerated airway inflammation 
with significant increased production of Th2 cytokines (160). To define the effect of Etv5 
on Th2 cells in vivo, we sensitized mice with A. fumigatus extract every other day for 21 
days to induce type 2 inflammation (Figure 15A). One day following the final challenge, 
we collected and counted BAL cells. There was no difference in cell numbers between 
control mice and mice that had Etv5-deficient T cells (Figure 15B). However, the IL-10-
producing CD4+ T cell population was significantly decreased in mice that had Etv5-
deficient T cells in both BAL and lung, compared to control mice (Figure 15C). This result 
was consistent with decreased IL-10 present in the BAL fluid in mice with Etv5-deficient T 
cells (Figure 15E). However, Etv5 deficiency did not affect the production of IL-4 in vivo 
(Figure 15C-D). These data demonstrated that Etv5 plays a crucial role in regulating IL-
10 production in vivo. 
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Figure 15. Etv5 deficient Th2 cells produce less IL-10 in A. fumigatus extract-induced airway inflammation. (A) Control and Etv5fl/fl CD4 Cre+ mice were intranasally challenged with A.fumigatus extract every other day for 21 days. (B) Total cell count in the BAL of A.fumigatus extract-challenged control and Etv5fl/fl CD4 Cre+ mice. (C-D) Lung and BAL cells were stimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. Representative dot plots (C) and average percentage of IL-10 producing Th2 cells in BAL and lung (D) are indicated. Cells for flow cytometric analysis were gated on lymphocyte size and granularity, and the expression of CD4 and TCR. (E) IL-10 production of BAL cells was measured using ELISA. Data are mean ± SEM of 6 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pairwise comparisons. *p < 0.05, **p <0.005. 
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Etv5 directly binds to the Il10 locus and promotes IL-10 production 
The Il10 gene locus consists of a promoter and several CNS regions (28). Previous 
studies reported that several IL-10 inducing transcription factors bind to the Il10 locus and 
promote Il10 expression (136-139). Specifically, CNS3 is a primary target region of IL-10-
inducing transcription factors and critical for IL-10 regulation (Figure 16A). To test the 
ability of Etv5 to directly activate gene expression from Il10 regulatory elements, we co-
transfected 293T cells with Etv5 expressing vector and reporter vector containing the Il10 
promoter or CNS3 region. Etv5 significantly increased CNS3 reporter activity but did not 
activate the Il10 promoter reporter activity (Figure 16B). We then tested whether Etv5 
directly binds to the the Il10 promoter and CNS3 region using ChIP assay. Etv5 strongly 
bound to CNS3 region in Th2 cells but not in Th0 cells that have the minimal expression 
of IL-10 (Figure 16C and data not shown). As a control, Etv5 did not bind to several 
regulatory elements at the Il4 locus, consistent with a lack of altered IL-4 production in Th2 
cells lacking Etv5 (Figure 16C). These data suggest that Etv5 directly binds to the Il10 
CNS3 region and promotes gene expression from binding this element. 
 
Figure 16. Etv5 binds to the Il10 locus in Th2 cells. (A) Schematic of the Il10 locus. (B) Luciferase activity of 293T cells transfected with Etv5 expressing vector or control vector along with Il10 locus reporter vectors. (C) ChIP analysis of Etv5 binding to the Il10 and Il4 loci in Th2 or Th0 cells. Data are mean ± SEM of two independent experiments or 4 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pairwise comparisons. *p < 0.05. 
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Etv5 recruits IL-10-inducing transcription factors onto the Il10 locus  
Although the reporter assay would suggest that Etv5 can directly activate the Il10 
gene, it is also possible that Etv5 regulates the expression of other transcription factors 
that are required for IL-10 expression. To determine whether Etv5 regulates the 
expression of those transcription factors, we measured gene expression of the 
transcription factors in control or Etv5-deficient Th2 cells. The expression of Nfil3, a global 
IL-10 regulator that encodes E4BP4, was not affected by Etv5 deficiency (Figure 17A). 
Similarly, gene expression of other transcription factors was not affected by Etv5 
deficiency (Figure 17A).  
Despite normal expression of other IL-10-inducing transcription factors, it was still 
possible that they were not able to bind to the Il10 locus in the absence of Etv5. To test 
whether these factors were still binding the Il10 locus in the absence of Etv5, we used 
ChIP assays to assess binding in control and Etv5-deficient Th2 cells. E4BP4 bound to 
the Il10 promoter, intronic region (+2.5 kb) and more strongly CNS3 region in wild type 
Th2 cells (Figure 17B). However, in absence of Etv5, E4BP4 failed to bind to these regions, 
suggesting that Etv5 deficiency affected the binding of E4BP4 across the entire Il10 locus, 
especially at the CNS3 region. In the CNS3 region, recruitment of all transcription factors 
was significantly decreased in Etv5 deficient Th2 cells (Figure 17C). Etv5-deficient Th2 
cells also showed decreased H3K4me3. (Figure 17D). p300 strongly bound to the CNS3 
region, but binding was greatly decreased in Etv5-deficient Th2 cells (Figure 17D). Histone 
3 lysine 14 acetylation, linked to p300 activity, was also significantly decreased in Etv5 
deficient Th2 cells (Figure 17D). Thus, Etv5 is required for the maximal binding of IL-10-
inducing transcription factors to the CNS3 region in Th2 cells.  
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Figure 17. Etv5 enhances the binding of IL-10-inducing transcription factors. (A) Expression of IL-10-inducing transcription factors in control and Etv5fl/fl CD4 Cre+ Th2 cells were measured using qRT-PCR. (B-D) ChIP analysis of E4BP4 (B), IL-10 inducing transcription factors (C), or histone modifications and p300 (D) at the Il10 locus in WT or Etv5-deficient Th2 cells. Data are mean ± SEM of 4 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pairwise comparisons. *p < 0.05, **p <0.005. 
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Etv5 functionally cooperates with GATA3 and E4BP4 
The diminished binding of multiple transcription factors to the Il10 locus suggests 
that transduction of those factors into Etv5-deficient T cells would also have diminished 
effects. To test this directly, we ectopically introduced Etv5, E4BP4, or GATA3 into wild 
type or Etv5-deficient Th2 cells using retroviral transduction and measured IL-10 
production using intracellular staining. In wild type Th2 cells, ectopic expression of each 
factor significantly promoted IL-10 production (Figure 18A-B). In Etv5-deficient Th2 cells, 
ectopic Etv5 expression rescued IL-10 production to control levels (Figure 18A-B). Ectopic 
expression of GATA3 and E4BP4 increased IL-10-producing cells, but effects were still 
decreased in the absence of Etv5, compared to wild type Th2 cells. These data further 
support an important role for Etv5 in the appropriate functions of GATA3 and E4BP4 in 
Il10 regulation. 
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Figure 18. Etv5 deficiency decreases the ectopic expression effects of IL-10 inducing transcription factors. WT and Etv5-deficient naïve CD4+ T cells were cultured under Th2 cell condition for 5 days. After one day of culture, cells were transduced with control or transcription factor-expressing retrovirus. On day 5, cells were restimulated with PMA/ionomycin for 6 hours to assess IL-10 production using intracellular staining analysis. (A) Average percentage of IL-10 producing cells and (B) representative of flow cytometry image of data in (A). Data are mean ± SEM of 3 mice per group and representative of three independent experiments. A two-tailed Student t test was used for pairwise comparisons. *p < 0.05, **p <0.005. 
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Ectopic Etv5 expression restores its function in Etv5 deficient Th2 cells 
Our data suggests that IL-10-inducing transcription factors require Etv5 for optimal 
binding to the Il10 locus and IL-10 induction. To test whether re-introduction of Etv5 
rescues the binding of other transcription factors to the Il10 locus, we introduced Etv5 into 
Etv5 deficient Th2 cells using retroviral transduction followed by ChIP assay. Etv5 deficient 
Th2 cells infected by empty virus showed decreased binding of IRF4, GATA3 and E4BP4 
at the CNS3 region, compared to wild type Th2 cells infected by the same virus (Figure 
19), consistent with data in Figure 17C using non-transduced cells. Importantly, ectopic 
Etv5 expression in Etv5-deficient Th2 cells restored the binding of all three transcription 
factors at the CNS3 region indicating that Etv5 plays a pivotal role in regulating the binding 
of transcription factors to the Il10 locus.  
 
 
Figure 19. Ectopically introduced Etv5 in Etv5-deficient Th2 cells increases transcription factor binding to the Il10 locus. After one day of culture, Etv5-deficient Th2 cells were transduced with control or Etv5 expressing retrovirus. On day 5 of culture, ChIP assay was performed to examine transcription factor binding at the Il10 locus. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pairwise comparisons. *p < 0.05, **p <0.005. 
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Part III. Identification of novel enhancers for Il9 gene expression in T cells 
 
p300 ChIP and ChIP-seq  
Enhancers function independent of their location which makes identification of 
enhancers more challenging. To narrow down enhancer candidates for Il9 gene 
expression, we used several strategies. Because enhancers are highly conserved 
between species, we screened CNSs around the Il9 locus using evolutionary conservation 
of region (ECR) browser. In addition to CNS+5.5 and CNS-6, a region 25 kb upstream of 
the Il9 TSS in mice is highly conserved with a -18 kb region of the human Il9 gene (Figure 
20A). p300 binding is an indicator of active enhancers (111). To examine the binding of 
p300 across the Il9 locus, p300 ChIP assay was performed in T cell subsets. In Th9 cells, 
p300 strongly bound to CNS-25, CNS-6 and the Il9 promoter (Il9p) (Figure 20B). 
Consistent with p300 ChIP analysis, p300 ChIP-seq data showed strong signals at the 
CNS-25, CNS-6 and Il9 promoter (Figure 20C). We examined this region in Th2 cells using 
publically available data (GSE 22104 (8)/ GSE 40463 (123)). We observed signals for 
p300 and H3K4me1 at the CNS-25 and CNS-6 but not at the Il9 promoter, consistent with 
low or absent Il9 expression in Th2 cells. STAT6 binding was also observed at the CNS-
25 and CNS-6.     
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Figure 20. p300 binds to the CNS-25, CNS-6 and the Il9 promoter. (A) Schematic of the mouse Il9 locus and conserved regions with the human IL9 locus. (B) Naïve CD4+ T cells were isolated from WT mice and cultured under different Th cell polarizing conditions. On day 5, cells were harvested for ChIP analysis using p300 antibody. ChIP analysis of p300 at the CNS regions of the Il9 locus and at -12 kb, -35 kb regions for negative control. Percent input depicted are the histone modification ChIP values after subtraction of the control IgG ChIP values. (C) ChIP seq analysis of p300 in Th9 cells and p300, STAT6 and H3K4me1 in Th2 cells. Data are mean ± SEM (n=4/experiment). One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. **p <0.01, ***p <0.001 
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Analysis of CNS-25 enhancer activity  
Based on p300 ChIP and ChIP-seq analysis, we hypothesized that the CNS-25 
region might be an enhancer for Il9 gene. To test whether CNS-25 has an enhancer 
activity, dual luciferase reporter assays were performed. We co-transfected EL4 cells with 
the Il9p reporter vectors with or without CNS-25, and an IRF4 expression vector. 
Consistent with previous reports, IRF4 significantly increased Il9p activity (Figure 21A). In 
the absence of IRF4, CNS-25 did not enhance Il9p activity. However, when co-transfected 
with IRF4, CNS-25 significantly enhanced Il9p activity. Because enhancers function 
independently of their direction and location, Il9p reporter vector was modified by adding 
reverse direction of CNS-25 into upstream of Il9 promoter or 3’ of the luciferase gene. 
Regardless of direction and location, CNS-25 significantly enhanced IRF4-induced Il9p 
activity. These data suggest that CNS-25 has an enhancer activity. BATF and IRF4 
cooperate to bind to an AICE element in the Il9 promoter and promote Il9 gene expression 
(54). After screening AICE sites in CNS-25 region, the IRF4 consensus sequence in these 
sites were point mutated in a CNS-25-Il9p reporter vector (Figure 21B). After co-
transfection of EL4 cells with these vectors and IRF4 expression vector, Il9p reporter 
activities were measured. AICE#1~#3 mutations caused modest decrease in Il9p reporter 
activities. Point mutations in AICE#4~#7 did not affect Il9p activity. Next, we deleted 
sequences between AICE#1 and AICE#2 (25bp), AICE#3 and AICE#5 (40bp), AICE#6 
and AICE#7 (85bp) in the CNS-25-Il9p reporter vector (Figure 21C). After co-transfection 
of EL4 cells with these vectors and IRF4 expression vector, Il9p reporter activities were 
measured. Similar to the point mutations in AICEs, deletion of AICEs showed only modest 
and insignificant decreases in Il9p reporter activity. These data suggest that these sites 
might not be actual AICEs. Another possibility is that point mutations or deletions of AICEs 
in CNS-25 might not be sufficient for a significant effect on the Il9 reporter activity because 
of redundancy of AICEs. 
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Figure 21. CNS-25 enhances Il9 promoter activity. 
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Figure 21. CNS-25 enhances Il9 promoter activity. (A) EL4 T cells were transfected with IRF4 expressing vector or control vector along with the Il9 locus reporter vectors following activation with PMA/ionomycin for 6 hours to assess reporter activities. (B) Schematic of the CNS-25-Il9p reporter vector with point mutations in AICE candidates and their effects on Il9p activity (C) Schematic of the CNS-25-Il9p reporter vector with deletions of AICE candidates and their effects on Il9p activity. Data are mean ± SEM of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01, ***p <0.001 
 
 
 
Histone modifications and the binding of transcription factors at the Il9 locus 
Previous studies showed that active enhancers have opened chromatin status with 
active histone modifications such as H3K4me1 and H3K27ac (127). These histone 
modifications change closed chromatin, called heterochromatin, to opened chromatin, 
called euchromatin, which allows TFs to bind to accessible DNA (111).  
To determine the chromatin status of CNS-25 in T cell subsets, ChIP assays were 
performed using antibodies against active enhancer marks H3K4me1 and H3K27ac, and 
repressive mark H3K27me3. Both H3K4me1 and H3K27ac modifications at the CNS-25 
were significantly higher in Th9 cells than other T cell subsets (Figure 22B). In contrast, 
H3K27me3 was significantly lower at both CNS-25 and Il9 promoter in Th9 cells compared 
to other T cell subsets. These results indicate that the CNS-25 has an activated and 
opened chromatin status in Th9 cells which allow TFs easily get access to this region. 
Next, we measured H3K4me3, an active promoter marker, to determine whether CNS-25 
has a promoter activity. H3K4me3 was the highest at the Il9 promoter in Th9 cells among 
T cell subsets. However, H3K4me3 was much lower at the CNS-25 than at the Il9 promoter 
in Th9 cells suggesting that CNS-25 does not have a promoter activity. The histone 
modification analyses further support that CNS-25 is an Il9 enhancer.   
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Figure 22. Active histone modifications at the Il9 locus in Th cell subsets. Naïve CD4+ T cells were isolated from WT mice and cultured under different Th cell polarizing conditions. On day 5, cells were harvested for ChIP analysis using H3K4me1, H3K27ac, H3K27me3 and H3K4me3 antibodies. (A) Schematic of the Il9 locus in mice. (B) ChIP analysis of histone modifications at the Il9 locus. Data are mean ± SEM (n=4/experiment). One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons. *p < 0.05, **p <0.01, ***p <0.001 
 
 
 
In addition to specific histone modifications, active enhancers are co-occupied with 
many TFs (111). The results of histone modifications at the CNS-25 suggest that Il9 
inducing TFs might bind to the CNS-25. To examine this, further ChIP assays were 
performed to measure the binding of TFs such as BATF, IRF4, STAT6, STAT5 and PU.1. 
Consistent with previous reports (54, 55, 59, 90), BATF, IRF4, STAT6, STAT5 and PU.1 
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strongly bound to the Il9 promoter in Th9 cells (Figure 23B). Interestingly, BATF, IRF4, 
STAT6 and STAT5 also strongly bound to the CNS-25 in Th9 cells. However, PU.1 binding 
was not detected at CNS-25. 
 
 
Figure 23. IL-9-inducing transcription factors co-occupy the Il9 locus in Th9 cells. Naïve CD4+ T cells were isolated from WT mice and cultured under different Th cell polarizing conditions. On day 5, cells were harvested for ChIP analysis using STAT6, STAT5, IRF4, BATF and PU.1 antibodies. (A) Schematic of the Il9 locus in mice. (B) ChIP analysis of the binding of transcription factors at the Il9 locus. Data are mean ± SEM (n=4/experiment). One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons.  *p < 0.05, **p <0.01, ***p <0.001 
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Effects of STAT6 and IRF4 deficiency on CNS-25 chromatin modifications   
Previous studies revealed that STAT6 and IRF4 are critical IL-9-inducing factors. 
Both STAT6 and IRF4 deficient CD4+ T cells cultured under Th9 condition showed 
dramatically reduced IL-9 production (55, 90). To examine the effects of STAT6 and IRF4 
deficiency on CNS-25 chromatin modifications, ChIP assays were performed. Either 
STAT6 or IRF4 deficient Th9 cells failed to recruit p300 and BATF to the CNS-25 (Figure 
24A & B). Moreover, H3K4me1 level was also significantly decreased in these cells which 
might result in failure of the activation of CNS-25.    
 
 
Figure 24. IRF4 and STAT6 are important for mediating chromatin modifications at the CNS-25. Naïve CD4+ T cells were isolated from Irf4fl/fl Lck Cre+, STAT6 KO and WT mice and cultured under Th9 cell polarizing condition. On day 5, Irf4fl/fl Lck Cre+ (A) or STAT6 KO (B) Th9 cells cells were harvested for ChIP analysis using p300, BATF and H3K4me1 antibodies. Data are mean ± SEM of 4 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01, ***p <0.001 
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CNS-25 is critical for regulating Il9 gene expression in vitro 
To define the function and specificity of CNS-25 for Il9 gene expression, CNS-25 
germline deficient (Il9 ΔCNS-25) mice were generated by Taconic using a CRISPR/Cas9 
approach. (Figure 6). Mutant mice were bred to homozygosity and appeared normal. 
Lymphoid organ cellularity and composition appeared normal. Proliferation rate and 
viability of T cells were normal (data not shown). First, we compared IL-9 production in Th 
cell subsets between Il9 ΔCNS-25 mice and their littermates as a wild type control. After 
isolation of naïve CD4+ T cells from these mice, cells were cultured under the indicated 
Th cell conditions for 4 or 5 days. On day 4 or day 5, IL-9 production of Th cell subsets in 
wild type and Il9 ΔCNS-25 mice was analyzed using intracellular staining. IL-9 production was 
significantly decreased by about 75% in Il9 ΔCNS-25 Th9 cells compared to wild type Th9 
cells on day 4 (Figure 25A, 25B). This defect in IL-9 production by Il9 ΔCNS-25 Th9 cells on 
day 4 was similar in the presence or absence of anti-IL-10R neutralizing antibody on day 
5 (Figure 25A, 25B).  
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Figure 25. CNS-25 deletion impairs IL-9 production in Th9 cells. Naïve CD4+ T cells were isolated from WT or Il9 ΔCNS-25 mice and cultured under Th9 cell polarizing condition with or without anti-IL-10R antibody. (A) On day 4 or day 5, cells were restimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. (B) Average percentage of IL-9 producing T cells in total CD4+ T cells. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01, ***p <0.001 
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To confirm flow cytometry data, the amount of IL-9 in the supernatant and Il9 gene 
expression in Th9 cells were measured using ELISA and qRT-PCR, respectively. 
Consistent with flow cytometry data, the amount of IL-9 and Il9 gene expression level were 
significantly decreased in Il9 ΔCNS-25 Th9 cells on day 4 and day 5 (Figure 26 and 27). 
However, IL-4 and IL-10 production and their gene expression were not affected by CNS-
25 deletion suggesting that CNS-25 specifically regulates Il9 expression (Figure 26 and 
27).  
 
 
Figure 26. IL-9 production was impaired by CNS-25 deletion in Th9 cells. Day 4 (A) or day 5 (B) cultured Th9 cells were restimulated with anti-CD3 overnight to assess cytokine production by means of ELISA. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01, ***p <0.001 
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Figure 27. Il9 gene expression was impaired by CNS-25 deletion in Th9 cells. Day 4 cultured Th9 cells with (A) or without anti-IL10R antibody (B) were restimulated with anti-CD3 for 6 hours to measure cytokine gene expression using qRT-PCR. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01 
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To exclude the possibility that CNS-25 deletion affects Il9 expression by altering 
TF expression, TF gene expression was measured using qRT-PCR. Batf, Irf4, Stat6 and 
Sfpi1 gene expression were similar between wild type and Il9 ΔCNS-25 Th9 cells (Figure 28A). 
Additionally, gene expression of IL-9 repressing TFs such as T-bet, Foxp3, RORc, Bcl6, 
Runx3, Id3 and IRF1, were also not affected by CSN-25 deletion (Figure 28B). These data 
strongly indicate that CNS-25 specifically regulates Il9 expression without affecting other 
cytokine or TF expression which might affect Th9 cell development. 
 
 
Figure 28. CNS-25 deletion does not affect gene expression of TFs regulating Il9 expression in Th9 cells. On day 4, Th9 cells were restimulated with anti-CD3 for 6 to measure cytokine gene expression using qRT-PCR. The gene expression of IL-9-inducing (A) or repressing (B) TFs in WT and Il9 ΔCNS-25 were measured using qRT-PCR. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01, ***p <0.001 
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Next, we studied the effect of CNS-25 deletion on Il9 expression in other Th cell 
subsets. Human Th17 cells produce IL-9 in response to IL-10 and pro-inflammatory 
cytokines, and murine Th17 cells also produce IL-9 (98, 161). As a previous report showed, 
Th17 cells produced IL-9 although the expression was much less than in Th9 cells 
(compare Figure 29 to Figure 25 and 26). However, Il9 ΔCNS-25 Th17 cells barely produced 
IL-9. And CNS-25 deletion did not affect IL-17 production. To confirm this cytometry data, 
the amounts of IL-9 and IL-17A in the supernatant of Th17 cells were measured by ELISA. 
IL-9 production was significantly decreased in Il9 ΔCNS-25 Th17 cells, however IL-17A 
production was not changed (Figure 29C, 29D). Additionally, the gene expression of Il17a 
and Rorc were also not altered in Il9 ΔCNS-25 Th17 cells (Figure 30). 
 
 
Figure 29. CNS-25 deletion impairs IL-9 production in Th17 cells. Naïve CD4+ T cells were isolated from WT or Il9 ΔCNS-25 mice and cultured under Th17 cell polarizing condition. On day 4, cells were harvested for analysis. (A) Cells were restimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. (B) Average percentage of IL-9 producing T cells in total CD4+ T cells. Day 4 (C) or day 5 (D) cultured Th17 cells were restimulated with anti-CD3 overnight to assess cytokine production by means of ELISA. Data are mean ± SEM of 3 mice per group and representative of two 
A B
C D
78 
independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01, ***p <0.001. N.D., not detected. 
 
 
 
 
Figure 30. CNS-25 deletion does not affect the gene expression of Il17a and Rorc in Th17 cells. Day 4 cultured Th17 cells were restimulated with anti-CD3 for 6 hours to measure cytokine gene expression using qRT-PCR. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. **p <0.01, ***p <0.001 
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In contrast to the effects of CNS-25 deletion in Th9 and Th17 cells, Il9 ΔCNS-25 Th2 
cells produced more IL-9 than wild type Th2 cells although still much less than Th9 cells 
(compare Figure 31 to Figure 25 and 26). However, Il9 ΔCNS-25 Th2 cells produced normal 
amount of IL-4. To confirm this cytometry data, the amounts of IL-9 and IL-4 in the 
supernatant of Th2 cells were measured by ELISA (Figure 31C, 31D). IL-9 production was 
significantly increased in Il9 ΔCNS-25 Th2 cells, however IL-4 production was not changed. 
Additionally, the gene expression of Il4 and Gata3 were not altered in Il9 ΔCNS-25 Th2 cells 
(Figure 32). These data suggest that CNS-25 might act as a repressor of Il9 gene 
expression in Th2 cells. 
 
 
Figure 31. Deletion of CNS-25 promotes IL-9 production in Th2 cells. Naïve CD4+ T cells were isolated from WT or Il9 ΔCNS-25 mice and cultured under Th2 cell polarizing condition. On day 4, cells were harvested for analysis. (A) Cells were restimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. (B) Average percentage of IL-9 producing T cells in total CD4+ T cells. Day 4 (C) or day 5 (D) cultured Th2 cells were restimulated with anti-CD3 overnight to assess cytokine production by means of ELISA. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01, ***p <0.001 
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Figure 32. CNS-25 deletion does not affect the gene expression of Il4 and Gata3 in Th2 cells. Day 4 cultured Th2 cells were restimulated with anti-CD3 for 6 hours to measure cytokine gene expression using qRT-PCR. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. **p <0.01, ***p <0.001 
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We also examined whether CNS-25 deletion affects IL-9 production and the 
development of Treg and Th1 cells. To do this, Foxp3 and Ifng expression were measured, 
as hallmarks of Treg and Th1 cells respectively. Both Il9 ΔCNS-25 Treg and Th1 cells 
expressed normal Foxp3 and Tbx21, which suggest that the CNS-25 deletion does not 
affect Treg and Th1 cell development (Figure 33, 34). In Treg cells, Il9 gene expression 
was significantly decreased in Il9 ΔCNS-25 Treg cells, however Il10 expression was not 
altered (Figure 33). In Th1 cells, IL-9 was barely detected and there were no differences 
between wild type and Il9 ΔCNS-25 Th1 cells in either ICS or qRT-PCR (Figure 34). We 
compared Il9 expression in Th cell subsets and it was much higher in Th9 cells than other 
Th cell subsets (Figure 35). These results strongly indicate that CNS-25 is a critical 
enhancer for regulating Il9 expression in T cell subsets, especially in Th9 cells, without 
affecting other cytokines or TF expression which might affect Th9 cell development.  
  
 
Figure 33. Deletion of CNS-25 impairs IL-9 production in Treg cells. Naïve CD4+ T cells were isolated from WT or Il9 ΔCNS-25 mice and cultured under Treg cell polarizing condition. On day 4, cells were harvested for analysis. (A) Cells were stained with Foxp3. (B) Treg cells were restimulated with anti-CD3 for 6 hours to measure cytokine gene expression using qRT-PCR. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. ***p <0.001 
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Figure 34. Deletion of CNS-25 does not impair IL-9 production in Th1 cells. Naïve CD4+ T cells were isolated from WT or Il9 ΔCNS-25 mice and cultured under Th1 cell polarizing condition. On day 4, cells were harvested for analysis. (A) Cells were restimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. (B) Th1 cells were restimulated with anti-CD3 for 6 hours to measure cytokine gene expression using qRT-PCR. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons.  
 
 
 
 
Figure 35. Relative Il9 expression among Th cell subsets. Il9 expression in Th cell subsets was measured by qRT-PCR and normalized to β2m expression. 
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CNS-25 deletion attenuates allergic inflammation in asthma models 
To define the function of CNS-25 in vivo, the HDM and chronic A. fumigatus airway 
inflammation models were used.  
In the HDM extract-induced airway inflammation model, we intranasally challenged 
wild type, Il9 ΔCNS-25 and Il9 +/ΔCNS-25 mice with HDM extract 8 times, every other day for 16 
days (Figure 36A). The day following the final challenge, we collected and counted BAL 
cells (Figure 36B). The population of IL-9-producing CD4+ T cells in the lung was 
measured using intracellular cytokine staining, and it was significantly decreased in the 
lung of Il9 ΔCNS-25 mice, compared to wild type and Il9 +/ΔCNS-25 mice.   
In the A. fumigatus extract-induced airway inflammation model, we intranasally 
challenged wild type and Il9 ΔCNS-25 mice with A. fumigatus extract, 3 times a week for 6 
weeks (Figure 37A). The day after the final challenge, we collected and counted BAL cells 
(Figure 37B). The number of BAL cells was significantly decreased in Il9 ΔCNS-25 mice. The 
IL-9-producing CD4+ T cell population in BAL and lung was significantly decreased in Il9 
ΔCNS-25 mice (Figure 37C, 37D). These results strongly indicate that CNS-25 is a critical 
enhancer for promoting Il9 expression in CD4+ T cells in vivo. 
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Figure 36. CNS-25 deficient Th9 cells produce less IL-9 in HDM extract-induced airway inflammation. (A) WT, Il9 ΔCNS-25 and Il9 +/ΔCNS-25 mice were intranasally challenged with HDM extract every other day for 16 days. (B) Total cell count in the BAL. (C) Lung cells were restimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. Representative dot plots (C) and average percentage (D) of IL-9 producing CD4+T cells in the lung. Cells for flow cytometric analysis were gated on lymphocyte size and granularity, and the expression of CD4 and TCR. Data are mean ± SEM of 3 mice per group. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01 
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Figure 37. CNS-25 deficient Th9 cells produce less IL-9 in A. fumigatus extract-induced airway inflammation. (A) WT and Il9 ΔCNS-25 mice were intranasally challenged with A. fumigatus extract every other day for 42 days. (B) Total cell count in the BAL. (C-D) BAL and lung cells were restimulated with PMA/ionomycin for 6 hours to measure cytokine production using intracellular staining. Representative dot plots (C) and average percentage of IL-9 producing CD4+ T cells in BAL and lung (D). Cells for flow cytometric analysis were gated on lymphocyte size and granularity, and the expression of CD4 and TCR.  Data are mean ± SEM of 5 mice per group. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05 
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Effects of CNS-25 deletion on histone modifications and TF binding at the Il9 
promoter 
Both in vitro and in vivo data showed that CNS-25 is a critical enhancer for Il9 
expression. To define the molecular functions of CNS-25 on the Il9 locus in Th9 cells, 
histone modifications and the binding of IL-9-inducing TFs to the Il9 promoter were 
measured using ChIP assay. The active promoter markers H3K4me3 and H3K27ac were 
significantly higher in wild type Th9 cells than in Il9 ΔCNS-25 Th9 cells (Figure 38B). However, 
H3K27me3 was similar between groups. Consistent with Figure 23, IL-9-inducing TFs 
strongly bound to both CNS-25 and Il9 promoter in Th9 cells (Figure 39B). However, CNS-
25 deletion caused significantly less binding of the TFs in the Il9 promoter (Figure 39B). 
Based on the data, we conclude that CNS-25 is critical for the binding of TFs and histone 
modifications at the Il9 promoter. 
 
 
 
 
 
87 
 
Figure 38. CNS-25 deletion impairs active histone modification at the Il9 promoter. Naïve CD4+ T cells were isolated from WT or Il9 ΔCNS-25 mice and cultured under Th9 cell polarizing condition. On day 5, cells were harvested for ChIP analysis using H3K27ac, H3K27me3 and H3K4me3 antibodies. (A) Schematic of the Il9 locus in mice. (B) ChIP analysis of histone modifications at the Il9 locus. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01. N.D., not detected.  
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Figure 39. CNS-25 deletion impairs the binding of IL-9-inducing TFs at the Il9 promoter. Naïve CD4+ T cells were isolated from WT or Il9 ΔCNS-25 mice and cultured under Th9 cell polarizing condition. On day 5, cells were harvested for ChIP analysis using STAT6, STAT5, IRF4, BATF and PU.1 antibodies. (A) Schematic of the Il9 locus in mice. (B) ChIP analysis of the binding of TFs at the Il9 locus. Data are mean ± SEM of 3 mice per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05. N.D., not detected. 
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DNA Looping 
To function properly, enhancers need to be in proximity to a promoter and they 
accomplish this by making DNA loops (111). Med1, a mediator complex subunit, Smc1a, 
structural maintenance of chromosomes 1a, and CTCF, CCCTC binding factor, are all 
involved in making 3D DNA loop chromatin structure (148, 162). To provide evidence for 
DNA looping between CNS-25 and the Il9 promoter, ChIP assays were performed using 
Smc1a, Med1 and CTCF antibodies. These proteins strongly bound to both CNS-25 and 
the Il9 promoter in Th9 cells, suggesting that CNS-25 functions through a DNA loop 
(Figure 40).  
 
 
Figure 40. DNA loop mediating TFs bind to both CNS-25 and the Il9 promoter in Th9 cells. Naïve CD4+ T cells were isolated from WT mice and cultured under different Th cell polarizing conditions. On day 5, cells were harvested for ChIP analysis using Smc1a, Med1 and CTCF antibodies. (A) Schematic of the Il9 locus in mice. (B) ChIP analysis of the binding of at the Il9 locus. Data are mean ± SEM (n=4/experiment). One-way ANOVA with a post hoc Tukey test was used to generate p values for all multiple comparisons.  *p < 0.05, **p <0.01 
 
 
A 
B 
90 
Conserved Functions of IL9 CNS-18 in Human 
Cis-regulatory elements can be highly conserved between species (111). As 
shown in Figure 41A, the Il9 CNS-25 region in mice shows high homology with an IL9 
CNS-18 region in the human genome, suggesting that IL9 CNS-18 might have similar 
function of Il9 CNS-25. To measure chromatin status of IL9 CNS-18 in human T cell 
subsets, ChIP assays were performed using antibodies against H3K4me1 and H3K27ac. 
Both H3K4me1 and H3K27ac levels at the CNS-18, and H3K4me3 level at the IL9 
promoter were significantly higher in Th9 cells than in Th0 cells (Figure 41C).  
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Figure 41. Active histone modifications at the IL9 CNS-18 in human T cells. Naïve CD4+ T cells were isolated from human PBMCs and cultured under Th0 and Th9 cell polarizing conditions. On day 4, cells were harvested for ChIP analysis using H3K4me1, H3K27ac and H3K4me3 antibodies. (A) Schematic of CNSs in Il9/IL9 locus in mouse and human genomes (B) Schematic of the IL9 locus in human. (B) ChIP analysis of histone modifications at the IL9 locus. Data are mean ± SEM of 3 donors per group and representative of two independent experiments. A two-tailed Student t test was used for pair wise comparisons. *p < 0.05, **p <0.01 
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To prove whether IL9 CNS-18 is also critical for IL9 gene expression in human Th9 
cells, we applied the CRISPR/Cas9 system to delete CNS-18 region in primary human T 
cells. To do this, we generated a single lentiviral vector expressing Cas9 and gRNAs 
targeting CNS-18. Cas9 in this vector is fused with EGFP with a connecting sequence 
encoding the self-cleaving 2A peptide, so EGFP can be used as a marker for Cas9 
expression. Lentiviruses expressing both Cas9 and gRNAs targeting CNS-18 or targeting 
an irrelevant mouse DNA sequence for a negative control, were produced through 
transfection of HEK 293T cells. After infection of human Th9 cells with lentivirus, IL-9 
production between control and CNS-18 deleted Th9 cells were measured using ICS on 
day 4. Consistent with mouse experiments, CNS-18 deleted Th9 cells produced 
significantly less IL-9 compared to control Th9 cells (Figure 42A). Even though IL-9 
production in Th9 cells was different among donors, the pattern of IL-9 reduction after 
CNS-18 deletion was similar. The deletion efficiency of CNS-18 region was examined 
using ChIP primers for CNS-18 region and normalized to -12 kb sequence. The deletion 
efficiency was around 40 to 50% (Figure 42C). 
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Figure 42. Deletion of IL9 CNS-18 impairs IL-9 production in human Th9 cells. Naïve CD4+ T cells were isolated from human PBMCs and cultured under Th9 cell polarizing condition. After one day of culture, cells were transduced with lentivirus expressing Cas9 and gRNAs targeting CNS-18. On day 4, cells were restimulated with PMA/ionomycin for 6 hours to assess IL-9 production using intracellular staining analysis. (A) Representative of flow cytometry image of data (B). (B) Percentage of IL-9 producing CD4+ T cells from individual donors after IL9 CNS-18 deletion. (C) On day 4, Cas9 and gRNAs expressing Th9 cells were sorted based on EGFP expression. Deletion efficiency of IL9 CNS-18 was measured using qPCR with ChIP primer for CNS-18 and normalized to -12 kb sequence. Data are mean ± SEM of 5 donors per group. A ratio paired t test was used for pair wise comparisons. **p < 0.01 
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To confirm the ICS results, Cas9 and gRNAs expressing human Th9 cells were 
sorted based on EGFP expression on day 4, and mRNA was isolated for assessing 
cytokine expression. Consistent with the cytometry data, IL9 gene expression was 
significantly decreased in CNS-18 deleted Th9 cells (Figure 43), However, IL10 and IL21 
expression was not altered by CNS-18 deletion. Overall, these data strongly indicate that 
CNS-18 in human, highly conserved in mice, plays a key role for enhancing IL9 gene 
expression. 
 
 
Figure 43. Il9 gene expression was impaired by CNS-18 deletion in Th9 cells. On day 4, Cas9 and gRNAs expressing Th9 cells were sorted based on EGFP expression. Gene expression of cytokines was measured using qRT-PCR. Data are normalized to β2m expression. Data are mean ± SEM of 3 donors per group. A ratio paired t test was used for pair wise comparisons. *p < 0.05 
 
 
 
 
 
 
 
* 
95 
DISCUSSION 
For optimal differentiation and function of CD4+ T cells, lineage specific TFs and 
cis-regulatory elements cooperate to regulate gene expression (111). Here, we identified 
Etv5 as an IL-9- and IL-10-inducing TF in Th9 and Th2 cells, respectively. Etv5 binds to 
these gene promoters and CNS regions, suggesting that Etv5 not only directly promotes 
gene expression but also mediates active chromatin structure at the Il9 and Il10 gene loci.  
The Il9 locus consists of 3 CNSs: CNS-6, CNS+5.5 and the Il9 promoter. IL-9-
inducing TFs including PU.1 directly bind to the Il9 promoter and promote Il9 expression 
(155). Interferon regulatory factors such as IRF1 and IRF4 also bind to the CNS-6 and 
CNS+5.5 (163). We revealed that Etv5 binds to the CNS-6 and CNS+5.5, and recruits 
p300 to these regions which might contribute to active histone modifications. And Etv5 
cooperates with PU.1 to regulate Il9 expression in vitro and in vivo. 
Th9 cells may produce IL-10 though the amount varies with culture conditions. The 
Il10 locus consists of 4 CNSs and the Il10 promoter (136). The binding sites for Il10 
regulating TFs are spread across these sites. For example, GATA3 binds to the Il10 
promoter, intronic regions and CNS3 region (137). E4BP4 binds to the CNS2, CNS3 and 
intronic regions, but does not bind to the Il10 promoter (138). We revealed that Etv5 
promotes IL-10 production in Th1 and Th2 cells. In Th2 cells, Etv5 mainly binds to the 
CNS3 region and recruits p300 contributing to a permissive chromatin structure in CNS3. 
In the absence of Etv5, active histone modifications at the CNS3 are decreased, which 
impairs the binding of IL-10-inducing TFs. 
To further resolve Il9 regulation, we identified CNS-25, a novel enhancer for Il9 
expression in mice. CNS-25 specifically regulates Il9 expression without affecting the 
expression of other cytokines and TFs. CNS-25 promotes active chromatin modifications 
at the Il9 promoter, potentially through DNA looping. IL9 CNS-18 in the human genome, 
conserved with Il9 CNS-25, is also critical for IL9 expression in human Th9 cells. Overall, 
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we have identified that Etv5 regulates expression of multiple cytokines, and demonstrated 
that the Il9 CNS-25/IL9 CNS-18 elements are critical for Il9/ IL9 expression respectively.    
 
Part I. The ETS family transcription factors Etv5 and PU.1 function in parallel to 
promote Th9 cell development 
Transcription factors play an obligate role in defining the phenotype and function 
of Th cells. In this part, we have defined the contribution of the ETS family transcription 
factor Etv5 to the Th9 phenotype. Etv5 shares many functions with the ETS family factor 
PU.1 that we previously demonstrated was required for Th9 development (59, 101). Both 
Etv5 and PU.1 regulate IL-9 production, although they appear to work through different 
regulatory elements in the Il9 gene (Figure 44). Apart from IL-9, PU.1 and Etv5 regulate 
some common and some distinct genes associated with the Th9 phenotype. Moreover, T 
cells that lacked both Etv5 and PU.1 had decreased IL-9 production in vitro.  
The concept of transcription factors from the same family having overlapping 
functions is observed in other T cells. In Th17 cells, the loss of IL-17 production is more 
severe in mice that lack both RORγt and RORα than either factor individually (152). 
Similarly, Tc17 cells develop from CD8 T cells that are doubly deficient in the T-box factors 
T-bet and Eomesodermin (164). This paradigm is also seen among ETS family factors 
that are divided into four classes based on binding sequence and nine subfamilies based 
on homology (165). The partial redundancy between PU.1 and Spi-B, two factors in the 
same subfamily, has been examined in several models including myeloid and lymphoid 
cell development, B cell function, and the development of leukemia (166-169). Other 
examples of factors from the same subfamily having overlapping function include Etv1 
and Etv4 that cooperate in prostate cancer, ELK1 and ELK4 in thymocyte development, 
and FLI-1 and ERG in hematopoiesis (170-172). However, PU.1 and Etv5 are from 
different subfamilies. This is not without precedent and ETS2 and ELF5, factors from 
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distinct subfamilies, cooperate in development (173). Some of this redundancy is clearly 
dependent on overlapping binding specificities of the family-defining DNA binding domain 
(174). Yet, the protein sequences outside of the DNA binding domain are divergent and 
suggest that the partial redundancies observed are limited by the ability of each ETS family 
member to interact with other transcription factors at gene-regulatory elements (165). 
 Although Etv5 and PU.1 were clearly cooperating on IL-9 production within in 
vitro–derived cells, we observed a trend but not a significant effect of Etv5 deficiency on 
IL-9 production in vivo. This could be caused by several reasons including compensation 
by increased the expression of PU.1 (Figure 11) or other signals in vivo that might bypass 
the requirement for Etv5 in the OVA/ alum model. Despite these data, we observed distinct 
effects of PU.1 and Etv5 on the overall allergic inflammation, suggesting that PU.1 and 
Etv5 are not exerting effects in vivo strictly through IL-9. This is consistent with the effects 
of deficiency of either factor or both in T cells during the development of allergic 
inflammation. Although deficiency in either factor results in diminished inflammation, PU.1 
deficiency had a slightly greater effect on eosinophil accumulation during allergic 
inflammation than did deficiency in Etv5. Conversely, Etv5 deficiency had a greater effect 
on neutrophil recruitment, consistent with our previous studies (107). Importantly, although 
we and others have shown that the HDM model of airway inflammation is dependent on 
IL-17 (107, 175), the OVA-alum model is largely IL-17 independent (176), so that the 
effects of Etv5 deficiency on IL-17 should not impact the total cellular inflammation in our 
studies. Both Etv5 and PU.1 contribute to the ability of Th9 cells to promote accumulation 
and gene expression of mast cells in lung tissue, again consistent with our previous results 
on the role of Th9 cells in mast cell accumulation in multiple models of allergic airway 
disease (57). We did observe that IL-13–producing T cells in the lung were also decreased 
in mice with T cells lacking both Etv5 and PU.1, although the proportion of these cells was 
not different, suggesting the decrease in number was linked to decreased overall 
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inflammation. IL-13 production from draining lymph node cells in mice with T cells lacking 
Etv5 and PU.1 was normal, leading to the conclusion that there is normal development of 
the Th2 response in these mice. Still, it is possible that the observed decrease in IL-13–
producing T cells might contribute some aspect of the diminished inflammation observed 
in vivo.  
Although we have focused on conventional CD4+ T cells in this part it is possible 
that Etv5 might be functioning in other types of cells. Other sources of IL-9 in the immune 
system include NKT cells, γδ T cells, and innate lymphoid cells (38). Among these, the 
CD4-Cre should only affect expression in NKT cells. We previously suggested that PU.1 
was not required for IL-9 production by NKT cells (57), but it is not clear whether Etv5 
might play a role within these cells. The role of NKT cells in asthma models is still debated, 
and what controls IL-9 within these cells is not yet clear.  
As noted earlier, the ETS transcription factor family is divided based on binding 
specificity and homology (165). As we have shown that PU.1 and Etv5 preferentially bind 
to different sites in the Il9 locus and recruit different HATs to the locus, they appear to 
have distinct functions at a convergent target gene. It is not clear whether this is a common 
theme among cooperating ETS factors. The ability of PU.1 and Etv5 to cooperate across 
subfamilies suggests that redundancy of function is not restricted to family members that 
have similar binding site specificities or similar structures outside of the common ETS DNA 
binding domain. PU.1 interacts with GATA3 and IRF4 in Th2 cells (139). PU.1-IRF4 and 
PU.1-GATA3 complexes are different because IRF4 does not interact with GATA3. These 
data suggest that PU.1 might interact with IRF4 at the Il9 promoter. BATF, another 
essential factor for Il9 expression, also binds to the AICE site in Il9 promoter suggesting 
that IRF4 is required for BATF binding at the Il9 promoter (54). IRF4 strongly binds to the 
CNS-6, CNS+5.5 and Il9 promoter (55, 163). We further revealed that BATF only binds to 
the Il9 promoter, not CNS-6 and CNS+5.5. PU.1 might interact with BATF or be required 
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for those TFs binding at the Il9 promoter. Interactions of Etv5 with IRF4 or BATF have not 
been studied yet. Etv5 might interact with IRF4 to regulate Il9 expression in CNS-6 and 
CNS+5.5. The functions of CNS-6 and CNS+5.5 are still not fully understood. These 
regions might be essential for inducing Il9 expression by mediating the Il9 locus chromatin 
conformation. Moreover, Etv5 might be important for the mechanism recruiting p300 to the 
CNS-6 and CNS+5.5 elements. Further work will help to elucidate the rules governing the 
development of evolutionary cooperation among this family of transcription factors.  
 
 
Figure 44. Etv5 and PU.1 regulate Il9 expression in Th9 cells through different regulatory elements in the Il9 locus  
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Part II. Etv5 regulates IL-10 production in Th cells 
IL-10 is a critical regulatory cytokine. In the absence of IL-10, mice develop 
spontaneous autoimmune inflammation (27). Thus, transcriptional control of the Il10 gene 
is essential in maintaining disease-free immune homeostasis (28). In this part, we identify 
Etv5 as a regulator of IL-10 in Th1 and Th2 cells, in vivo and in vitro. Etv5 binds directly 
to the Il10 locus and facilitates the binding of a number of other transcription factors that 
regulate IL-10 production (Figure 45).  
The regulation of IL-10 production may be distinct among subsets of Th cells. 
Previous reports identified several transcription factors that are involved in Il10 regulation 
in Th2 cells. GATA3 remodels the Il10 locus independently of IL-4 production in Th2 cells 
(137). JunB and c-Jun proteins bind to the CNS3 region in the Il10 locus and induce IL-10 
production in Th2 cells (136). In Th2 cells, IRF4 directly binds to the Il10 locus and 
promotes IL-10 production. E4BP4 is a reported universal IL-10 regulator in all Th cell 
subsets (138, 139). E4BP4 deficiency causes impairment of IL-10 production, but does 
not affect IL-13 production in Th2 cells. In this part, we add Etv5 to the list of factors that 
promote IL-10 production, and show that it works in concert with other factors by facilitating 
their binding to the Il10 locus. It is not clear if Etv5 functions by directly interacting with 
other transcription factors bound to the locus, or if it remodels chromatin allowing other 
transcription factors to bind more efficiently. Nevertheless, Etv5 is required for the other 
factors to optimally induce IL-10 production. 
Etv5 adds to a subset of ETS family transcription factors that regulate Il10. Ets-1 
represses IL-10 expression in Th1 cells by recruiting HDACs to the Il10 promoter and 
intronic regions (140). Polymorphisms in the human Il10 gene increase binding of the ETS 
factor Elk1 (177). PU.1 also negatively regulates IL-10 in Th2 and Th9 cells (100, 139). At 
least some of the mechanism of PU.1 function in Th2 cells is by interfering with IRF4 
binding to the Il10 locus regulatory elements (139). As each of these factors seems to 
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function through different mechanisms, and having different effects on IL-10, it seems 
unlikely that there would competition among them. This could be formally tested in future 
studies. 
Etv5 does not work in a subset specific manner, regulating IL-10 production in both 
Th1 and Th2 cells. Etv5 did not dramatically affect the lineage identifying cytokines for 
these Th subsets. This is in contrast to Etv5 function in Th17 where it is required for optimal 
expression of the lineage associated cytokines (107). We detected little IL-10 production 
from Th17 or Th9 cells in our culture conditions (data not shown), making it impossible to 
determine if Etv5 is contributing to Il10 expression in these subsets. This function might 
best be addressed in vivo in disease models where there are more IL-10-producing Th9 
and Th17 cells. 
Mice that have Etv5-deficient T cells clearly do not behave as IL-10-deficient mice. 
The Etv5fl/fl CD4 Cre+ mice do not develop spontaneous autoimmune inflammation. 
Moreover, A. fumigatus challenged Il10-/- mice showed exaggerated airway inflammation 
and excessive Th2 cytokines in BAL (160). In our studies, A. fumigatus extract-challenged 
Etv5fl/fl CD4 Cre+ mice demonstrated no difference in the overall inflammation, but had a 
reduced number of IL-10-producing T cells in the BAL and lung.  This is consistent with 
the partial role for Etv5 in IL-10 production that we observe in vitro and in vivo. The 
approximate 50% decrease in IL-10 production is not sufficient to result in the more 
dramatic effects of IL-10-deficiency in vivo. Additionally, in non-T cells, where Etv5 is not 
deleted, IL-10 production is likely normal, further attenuating the effects of the T cell-
specific deficiency of Etv5 in vivo. 
Our studies identify Etv5 as a promoter of IL-10 regulation in Th subsets. It binds 
to the Il10 CNS3 element, and facilitates the binding of several other IL-10-inducing factors 
that together control IL-10 production. This latest component of the Il10 enhancer complex 
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provides new insight into regulation of immunoregulatory cytokine production in Th 
subsets and could provide another potential target for modulating IL-10 production in vivo. 
 
 
Figure 45. Etv5 regulates Il10 expression in Th2 cells by recruiting IL-10-inducing factors 
to the Il10 CNS3 
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Part III. Identification of novel enhancers for Il9 gene expression in T cells 
TFs and cis-regulatory elements cooperate to regulate gene expression, In CD4+ 
Th cell subsets, cis-regulatory elements including enhancers and LCRs for cytokine 
expression were identified (111). Even though many Il9 regulating TFs have been 
identified, enhancers for Il9 gene expression had not been studied. Previous studies 
reported three CNS regions around the Il9 locus: Il9 promoter, CNS+5.5 and CNS-6 (155). 
Many studies focused on the Il9 promoter, and revealed that a few TFs can bind to the 
CNS-6 or CNS+5.5. These CNSs are marked by active histone modifications and co-
occupied with several TFs, suggesting that these regions might be enhancers for Il9 
expression. However detailed functions of these regions were not studied yet. In this part, 
we identified Il9 CNS-25/ IL9 CNS-18 as novel enhancers for Il9/ IL9 expression in mouse 
and human Th9 cells.  
Enhancers function independent of their direction and location which make it 
challenging to identify them. Previous studies proved that active histone modifications 
such as H3K4me1, H3K27ac and p300 binding are active enhancer marks (8, 127, 132). 
Moreover, enhancers are evolutionally conserved between different species.  
After screening CNSs in the Il9 locus between the mouse and human genomes 
using the ECR browser (online tool for visualizing whole genome alignments of multiple 
vertebrates), we detected CNS located 25 kb upstream of the Il9 TSS, termed as CNS-25. 
To define whether the region has enhancer features, we examined p300 binding in Th 
subsets using ChIP assay and ChIP seq. We could see strong binding of p300 at the CNS-
25, CNS-6 and Il9 promoter in Th9 cells. H3K4me1 and H3K27ac modifications at the 
CNS-25 were significantly higher in Th9 cells. H3K27me3, a repressive mark, was 
significantly lower at the CNS-25 and Il9 promoter in Th9 cells. Moreover, IL-9-inducing 
TFs also strongly bound to the CNS-25 and Il9 promoter in Th9 cells. These ChIP analyses 
suggest that CNS-25 has active enhancer features in Th9 cells.  
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To identify the function of CNS-25, we generated CNS-25 deletion mice, termed 
as Il9 ΔCNS-25, using the CRISPR/Cas9 system. We examined the effects of CNS-25 
deletion on Il9 expression in Th cell subsets through ICS, ELISA and qRT-PCR. IL-9 
production and gene expression were significantly decreased in Th9, Th17 and Treg cells 
from Il9 ΔCNS-25 mice. Effects of CNS-25 deletion on IL-9 production in Th9 cells were 
independent of the time point analyzed or culture conditions with or without αIL-10R 
antibody. The CNS-25 deletion did not affect the expression of other cytokines and TFs in 
all Th cell subsets, suggesting that CNS-25 specifically regulates Il9 expression. An 
opposite effects of the CNS-25 deletion was measured in Th2 cells. Il9 ΔCNS-25 Th2 cells 
produced more IL-9 compared to wild type Th2 cells while expressing normal level of IL-
4, suggesting that CNS-25 might act as a repressor of Il9 gene expression in Th2 cells.  
In this study, we showed that the function of CNS-25 is regulated by the binding of 
IL-9-inducing TFs. However, the function of CNS-25 also might be regulated by IL-9 
repressing TFs, because enhancer functions are regulated by both activating TFs and 
repressing TFs. One of known IL-9 repressing TFs is GATA3, however, the function of 
GATA3 in Il9 expression is still controversial. Even though ectopic expression of GATA3 
represses IL-9 production in Th9 cells, GATA3 deficient T cells failed to differentiate into 
Th9 cells (68, 90). Additionally, GATA3 binds to the Il9 promoter to promote Il9 expression 
(178). These data suggesting that the amount of GATA3 might be important for regulating 
Il9 expression. Existence of GATA3 binding candidate sites in CNS-25 and high Gata3 
expression in Th2 and Th9 cells suggest that GATA3 might bind to the CNS-25 and 
regulate Il9 expression in Th2 and Th9 cells. The DNA binding inhibitor Id3 negatively 
regulates Il9 expression by inhibiting the binding of GATA3 at the Il9 promoter in Th9 cells 
(178). As a repressor, Id3 might bind to the CNS-25 and repress Il9 expression in Th2 
cells. STAT3 is a negative regulator of IL-9 in Th9 cells and impairs the stability of Th9 
cells (97). In Th2 cells, however, STAT3 is required for the development and cytokine 
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expression of Th2 cells (179). We showed that STAT5 and STAT6 bound to the CNS-25 
in Th9 cells. Based on these data, we hypothesized that STAT3 might compete with 
STAT5 and STAT6 to bind to the CNS-25 and repress Il9 expression in Th2 cells.  
Next, we examined the function of CNS-25 in vivo airway inflammation models. 
We used HDM and A. fumigatus extract to induce airway inflammation. In both models, 
total number of BAL cells was significantly decreased in Il9 ΔCNS-25 mice. And, IL-9 
production was also significantly decreased in lung CD4+ T cells of Il9 ΔCNS-25 mice. In A. 
fumigatus-induced airway inflammation model, IL-9 producing CD4+ T cells in BAL was 
also decreased in Il9 ΔCNS-25 mice. These data showed that CNS-25 is essential for IL-9 
production in CD4+ T cells in vivo. In addition to Th9 cells, ILC2, NKT and mast cells 
produce IL-9 (67, 83-87). CNS-25 deletion might impair IL-9 production by these cells 
which might attenuate airway inflammation in these models.  
Next, we studied the molecular mechanisms by which CNS-25 may function in 
regulation Il9 expression. To do this, we compared the levels of H3K27ac, H3K4me3, and 
the binding of TFs at the Il9 promoter between wild type and Il9 ΔCNS-25 Th9 cells. As 
expected, active histone marks and the binding of TFs were significantly decreased in Il9 
ΔCNS-25 Th9 cells. These data indicate that CNS-25 mediates active histone modifications 
at the Il9 promoter which promote the binding of IL-9-inducing TFs to the Il9 promoter. 
H3K27me3 modification at the Il9 promoter in both wild type and Il9 ΔCNS-25 Th9 cells was 
much less compared to negative control regions (-35 and -12 kb regions). This indicates 
that H3K27me3 function was not altered by CNS-25 deletion. IL-9-inducing TFs still bound 
to the Il9 promoter in Il9 ΔCNS-25 Th9 cells, but much lower level than in wild type Th9 cells. 
This might contribute to maintain basal level of H3K27me3 which leads to produce more 
IL-9 in Il9 ΔCNS-25 Th9 cells than in other Th cell subsets.  
Enhancers function by looping to the promoter and many proteins are involved in 
this process. To establish whether CNS-25 is a part of a DNA loop, we examined the 
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binding of CTCF, Smc1a and Med1 at the CNS-25 and Il9 promoter in Th subsets. These 
proteins strongly bound to both CNS-25 and Il9 promoter in Th9 cells, suggesting that 
CNS-25 might interact with the Il9 promoter by making a DNA loop, which mediates active 
histone modifications at the Il9 promoter. However, these TFs did not bind to CNS-6, 
suggesting that CNS-6 might not be part of a DNA loop although active histone 
modification marks and the binding of IL-9-inducing TFs were measured. Further study 
will be required to identify functions of CNS-6. To get more clear evidence for a DNA loop 
at the Il9 locus, chromatin conformation capture assay (3C assay) will be performed in the 
future.  
The CNS-25 region in mice is highly conserved with CNS-18 in human. Because 
CNS-25 is critical for Il9 expression in mice Th9 cells, we hypothesized that CNS-18 has 
identical function in human Th9 cells. To test that, we deleted CNS-18 in primary human 
Th9 cells using the CRSIPR/Cas9 system. The efficiency of CNS-18 deletion was around 
40%, which might make it hard to detect deletion effects. However, CNS-18 deleted Th9 
cells produced significantly less IL-9 than control Th9 cells while expressing normal levels 
of IL10 and IL21. This data suggest that IL9 CNS-18 might be more critical for IL9 induction 
not just for enhancement, or other CNSs in IL9 locus in human might not be involved in 
IL9 expression.   
In mouse Th9 cells, pro-inflammatory cytokines and IL-10 act as negative 
regulators of Il9 expression. Th9 cells cultured with IL-10R blocking antibody and STAT3 
deficient Th9 cells produce higher IL-9 and maintain its expression long term in culture 
compare to normal Th9 cells (97). However, human Th9 cells produce more IL-9 in 
response to the pro-inflammatory cytokines such as IL-6, IL21 and IL-23, and IL-10 (98). 
Similar to this study, another report revealed that human Th17 cells produce more IL-9 
after adding pro-inflammatory cytokines (161). Based on these reports, we hypothesized 
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that STAT3 might bind to the CNS-18 and interact with other TFs to regulate IL9 
expression in human Th9 cells.  
Our studies demonstrated that the Il9 CNS-25 and IL9 CNS-18 are critical for 
Il9/IL9 expression in Th9 cells. Il9 CNS-25 mediates active histone modifications at the Il9 
promoter potentially through a DNA loop (Figure 46). Additionally, we revealed that CNS-
25 is critical for Il9 expression in airway inflammation models.  
 
 
Figure 46. CNS-25 regulates Il9 expression in Th9 cells through DNA loop 
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FUTURE DIRECTIONS 
The functions of cis-regulatory elements in the Il10 locus 
Th9 cells produce a high amount of IL-9 and IL-10 (38). Many studies have 
revealed TFs regulating the Il10 gene in Th cell subsets. However, the functions of cis-
regulatory elements in the Il10 locus were not fully understood. To define functions of Il10 
CNSs, mutant mice lacking these regions will be generated. After isolation of naïve CD4+ 
T cells from these mice, these cells will be cultured under Th cell conditions. IL-10 
production and gene expression between wild type and mutant Th cells will be compared 
using ICS, ELISA and qRT-PCR. To prove whether CNSs are clinically relevant, SNPs in 
Il10 CNSs of patients with ulcerative colitis or Crohn’s disease will be analyzed. If SNPs 
are located in binding sites for TFs at the Il10 CNSs, this could provide information about 
potential cooperation of the cis-regulatory elements at the Il10 locus and TFs in these 
diseases. Even in the absence of mice lacking Il10 CNSs, we can still examine the 
possibility of interactions between these regions with the Il10 promoter through 3C assay. 
Overall, these studies will provide more detailed molecular mechanisms of Il10 gene 
regulation.  
 
The functions of STAT3 and GATA3 in Th9 cells 
In this study, we identified Il9 CNS-25 as a novel enhancer for Il9 expression. We 
revealed that CNS-25 were co-occupied by many IL-9-inducing TFs in Th9 cells. And there 
is a high possibility that other Il9 regulating TFs can bind to the CNS-25. As discussed in 
discussion section, GATA3 might be linked to the function of the CNS-25. To prove 
whether GATA3 binds to the CNS-25 and mediates the Il9 locus conformation change in 
Th9 cells, GATA3 ChIP assay will be performed. If GATA3 binds to the CNS-25 region, 
the effects of knockdown of GATA3 on the 3D structure at the Il9 locus in Th9 cells will be 
measured using 3C assay. GATA3 promotes the Il9 promoter activity in a reporter assay 
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(178). To define whether GATA3 affects CNS-25 enhancer activity, reporter assay will be 
performed using GATA3 expressing vector and Il9 promoter reporter vectors with or 
without CNS-25. These studies will help us define additional roles of GATA3 for Il9 
expression. 
The functions of STAT3 might be different between mouse and human Th9 cells. 
To define functions of STAT3 in mouse and human Th9 cells, the binding of STAT3 at the 
Il9 CNS-25 and IL9 CNS-18 will be measured using ChIP assay. To measure STAT3 
activity, reporter assay will be performed using constitutively active STAT3 expressing 
vector and Il9 CNS-25-Il9 promoter or IL9 CNS-18-IL9 promoter vector. Through these 
studies, we will be able to define the different functions of STAT3 in mouse and human 
Th9 cells.  
 
Other cis-regulatory elements in the Il9 locus 
We have shown that CNS-6 also has enhancer features with strong binding of 
p300 and IRF4, high H3K27ac and low H3K27me3. Additionally, Etv5 also binds to the 
CNS-6. However, detailed functions of CNS-6 have not been studied yet. To prove 
whether CNS-6 has enhancer functions for Il9 expression, CNS-6 mutant mice will be 
generated. To define functions of CNS-6, similar experiments used to analyze function of 
CNS-25 will be performed. To study potential possibility of the interactions between CNS-
6 and Il9 promoter or CNS-6 and CNS-25, 3C assay will also be performed.   
 
The functions of CNS-25 in IL-9 producing non-T cells 
In addition to Th9 cells, many immune cells produce IL-9 (38). Il9 ΔCNS-25 mice are 
CNS-25 germline mutant mice, meaning that all IL-9 producing cells in the mice might be 
affected by the CNS-25 deficiency. One of IL-9 producing cells is mast cells. IL-9 is a 
growth factor for mast cells and it is also produced by mast cells. Bone marrow derived 
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mast cells (BMMCs) produce IL-9 (84). And multifunctional MMC9s were identified in IgE 
mediated food allergy experiment (87). To define the function of CNS-25 in mast cells, 
bone marrow cells from wild type and Il9 ΔCNS-25 mice will be isolated and cultured with stem 
cell growth factor (SCF) and IL-3 to selectively differentiate BMMCs. After 4 weeks culture, 
BMMCs will be stimulated with IL-33 to measure IL-9 production using ICS and ELISA. 
The expression of other cytokines such as IL-6 will be measured using qRT-PCR or ELISA 
to prove that CNS-25 specifically regulates Il9 expression.   
The functions of GATA1 are still controversial in mast cell. In human mast cells, 
GATA1 is essential for of FCER1A expression encoding FcεRIα (180). However, another 
report revealed that GATA1 is dispensable for mast cell differentiation in adult mice (181). 
In mouse mast cells, p38 kinase activates GATA1 contributing to IL-9 production (85). We 
confirmed GATA1 binding candidate sites in CNS-25 region. To examine whether GATA1 
is an essential TF for IL-9 production by binding to the CNS-25, GATA1 ChIP assay will 
be performed. To study whether GATA1 enhances Il9 promoter activity, reporter assays 
will be performed by co-transfecting mast cells with GATA1 expression vector and Il9 
promoter vectors with or without CNS-25.  In addition, the functions of GATA1 will be 
examined by overexpression or knockdown of GATA1 through lentiviral infection.  
ILC2s produce IL-9 in response to IL-33, IL-25 or papain (83). To study the 
functions of CNS-25 in ILC2, wild type and Il9 ΔCNS-25 mice will be intranasally challenged 
with IL-33 for 3 days. Following the last day of challenge, lung will be harvested for ICS 
and magnetic separation of ILCs. After separation, mRNA will be isolated to measure Il9 
gene expression using qRT-PCR. 
NKT cells, another lineage of IL-9 producing cells, will be studied by intranasal 
challenge of wild type and Il9 ΔCNS-25 mice with α-GalCer. 48 hours after challenge, BAL 
and lung cells will be isolated to measure IL-9 production using ICS. In addition to ICS, 
NKT cells will be isolated using CD1d tetramer specific fluorescent antibody and its micro 
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beads for magnetic separation. Then mRNA will be isolated to measure Il9 gene 
expression using qRT-PCR. 
Together these studies will further define IL-9 regulation in multiple lymphoid cell 
types and provide a basis for better understanding the mechanisms that control Il9 gene 
expression. Furthermore, these study will help us to develop treatments for IL-9 mediated 
allergic or autoimmune disease.  
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